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Abstract
ABSTRACT
Background: Cutaneous melanoma is an aggressive form of skin cancer, arising in
cutaneous melanocytes. The transcription factor PAX3 is critical for the proper
development of neural crest lineages including melanocytes. Melanocytic cells
show continued PAX3 expression from melanoblast formation in the neural crest
to their differentiation into melanocytes. While many studies clarify the
importance of PAX3 in embryonic development of melanocytes, less well
understood, and more perplexing, is the continued PAX3 expression in adult skin
melanocytes. By contrast PAX3 is frequently found in melanomas and naevi, and its
expression correlates with melanoma staging.
In this study we explore the multiple roles of PAX3 in melanocyte genesis and
melanoma progression. While PAX3 is known to regulate melanocyte
differentiation,

survival,

proliferation

and

migration

during

embryonic

development, it is not clear if these same functions are maintained in adult
melanocytes or melanoma cells. Drawing on evidence from development, we
propose here a more encompassing theory that PAX3 is a key regulator of the
myriad steps in melanocytic cell determination and function. We discuss the
possibility that these roles may be accomplished by differential association with
cofactors, via alternate transcripts or posttranslational protein modification(s).
Moreover, we consider its possible roles in melanoma and provide a
comprehensive consideration of the significance of PAX3 expression in melanoma.
Methodology and Principal Findings: In this study we firstly analysed the
expression of PAX3 across the spectrum of melanocytic cells, from normal
melanocytes to cells of benign and malignant lesions. PAX3 expression was
analysed by immunohistochemistry and RT‐qPCR. In order to get a better
understanding of PAX3 functions in these various tissues, we have characterised
PAX3‐expressing cells with respect to their proliferative, migratory and
antiapoptotic

potential,

as

well

as

differentiation

status.

For

this,

immunofluorescence was used to analyse PAX3 co‐expression with markers
representative of these processes that are also its downstream targets.
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As expected, PAX3 expression was observed in all naevi and melanoma samples,
but it was also found in both follicular and epidermal melanocytes of normal skin.
Melanocytic origin of PAX3‐expressing cells was confirmed by co‐expression with
known melanocyte markers, MITF and MLANA. Co‐expression with its
downstream target, antiapoptotic factor BCL2L1 confirmed PAX3 as a cell survival
regulator. PAX3 was also co‐expressed with melanoma cell migration marker
MCAM in dermal naevi, melanoma cell nests and normal melanocytes in growing
hair follicles, but this downstream target of PAX3 was not present in normal
epidermal melanocytes, suggesting differential roles for PAX3 in normal epidermal
melanocytes and melanoma cells. Most interestingly, a proportion of PAX3‐positive
epidermal melanocytes in normal skin show HES1 and Ki67 co‐expression,
indicating their less differentiated proliferative phenotype.
To clarify PAX3 roles in normal melanocytes and melanoma cells, we thought to
analyse its direct target genes in these cell types. An intensive literature research
was employed to identify the potential and likely PAX3 targets in normal
melanocytes and melanoma cells. This generated a list of 56 genes, from which we
selected 14 genes for further investigation, based on their significance for
melanoma development and progression. Direct PAX3 binding to the selected
genes in melanocytes and melanoma cells was assessed by ChIP‐qPCR. Differential
expression of identified direct targets was then analysed in melanoma cells
compared to normal melanocytes, by RT‐qPCR.
Results distinguish genes that are commonly regulated by PAX3 in melanocytes
and melanoma cells, from those that are restricted to melanoma cells. Further, we
show that similar to its role in development, PAX3 controlled complex
differentiation networks (via NES and SOX9) in both melanoma cells and
melanocytes, in order to maintain cells in a less differentiated, stem cell‐like state.
We also show that mediators of migration (MCAM and CSPG4) are common to both
cell types, but are more highly expressed in melanoma cells. By contrast, PAX3‐
mediated regulation of melanoma cell proliferation (through TPD52) and survival
(through BCL2L1 and PTEN) differs from that of melanocytes.
v
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Conclusions and Significance: Our results suggest that previously identified roles
for PAX3, as a regulator of an undifferentiated plastic state, and of cell
proliferation, migration and survival, may operate in melanoma cells as well as in
melanocytes of normal skin. By controlling these crucial cellular processes in
melanoma cells, PAX3 may contribute to development of malignant melanocytic
lesions and disease progression. Moreover its expression and action in normal
melanocytes may confer upon them a less differentiated, proliferative and motile
phenotype, thus predisposing them to aggressive malignant transformation.
Results presented here provide avenues for exploring PAX3 as a potential tool for
developing targeted therapy for melanoma treatment.
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Chapter I – Thesis Overview

Chapter I – Thesis overview
i.

GENERAL INTRODUCTION

Cutaneous melanoma
Cutaneous melanoma (it will be referred to in the remainder of the text as
‘melanoma’) is the most aggressive form of skin cancer arising from melanocytic
cells in the skin. While it represents only around 4% of all skin cancers, melanoma
accounts for nearly 80% of skin cancer related deaths [4]. Recent statistics are
alarming, showing that the worldwide incidence of melanoma is increasing at a
rate of 3‐7% per annum [5,6]. Australia has the highest incidence of melanoma in
the world, with Western Australia following closely behind Queensland [7]. Official
reports from the Western Australia Cancer Registry for the year 2008
(http://www.health.wa.gov.au/wacr) rate melanoma as the third most common
cancer overall (with 1082 new cases reported in 2008). It is the most common
cancer in young males and the second most common type in young females (age
15‐39). The 5‐year survival rate for early stage melanoma patients is high (around
95%), however, the fifteen year survival rate for some of those patients drops to
around 40%, and for advanced stage patients 5‐year survival is less that 20% [8,9].
It is important therefore to understand in detail the mechanisms driving
melanoma development and progression.
PAX3 transcription factor
PAX3 (paired box 3) is a paired box transcription factor, expressed during early
embryonic development in cells of neural crest origin, the cells which give rise to
skin melanocytes. In fact, PAX3 plays a key role in specification of melanoblasts
and in maintenance of their stem‐like/undifferentiated state. PAX3 also regulates
proliferation and migration to their final location in the skin, where they terminally
differentiate into melanocytes [10‐15]. PAX3 regulates these processes through
direct activation (or repression) of its downstream target genes which control
these pathways.
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While PAX3 expression and its roles during embryonic development have been
well described, its persistent expression in normal adult epidermal melanocytes
has been confirmed only recently [16‐18], and the precise role of PAX3 in these
cells is less well understood. It is possible that PAX3 controls maintenance [19] and
survival of melanocyte stem cells, required for continuous repopulation of skin
melanocytes, and facilitates their proper migration. It might also regulate survival
of differentiated epidermal melanocytes and their expansion/ proliferation in
response to sun exposure [20].
Notably, PAX3 is highly expressed in melanoma, and its expression correlates with
melanoma staging/progression [21‐26]. While PAX3 is known to contribute to
melanoma cell survival [27,28], it is not known whether it continues to control
pathways of differentiation, migration and proliferation in melanoma cells as it
does during embryonic development, and whether this contributes to melanoma
progression and metastatic spread. The analogy between developmental processes
and tumourigenesis, and the pivotal role that PAX3 has during melanocyte
development, has instigated us to further investigate PAX3 involvement in
melanoma development/progression. Furthermore, due to a lack of conclusive
information on the precise role of PAX3 in normal adult epidermal melanocytes,
the significance of its continued expression in normal melanocytes as they
progress through to melanoma is unknown. Further studies are required to
determine the causal relationship between PAX3 and tumourigenesis and to
determine the downstream molecular mechanisms involved in melanoma
metastasis.
Significance of the study
For melanoma patients complete surgical removal of a primary lesion is the first
line of treatment and this remains the most successful therapy [29]. Current
therapies for advanced melanomas have limited success, but new targeted
therapies are proving more successful [30‐34]. Identification of the key regulators
of melanoma progression would provide a tool for development of more effective
therapies to halt metastatic spread.
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PAX3 controls maintenance of the undifferentiated cell state, as well as
proliferation, migration and survival, throughout melanocyte development and
maturation. PAX3 might act similarly during melanoma‐genesis, ie as a key
intrinsic factor driving melanoma development and progression. We hypothesise
that its activity drives the cells towards an undifferentiated proliferative motile
state, which predisposes them to an aggressive phenotype upon malignant
transformation.
This study is aimed therefore at clarifying the role/s of PAX3 in normal
melanocytes and in melanoma cells. To achieve this aim we performed a detailed
analysis of PAX3 expression in normal skin and in various melanocytic lesions, and
identified downstream PAX3‐regulated targets and associated pathways in
melanocytes and in melanoma cells. Key differences, if any, in PAX3 function
between these two cell types, are likely to provide strategic clues to the process of
melanoma‐genesis.

3
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ii.

LITERATURE REVIEW

In order to uncover mechanisms of melanoma development and progression, we
first need to understand the regulatory mechanisms acting in normal cells from
which melanoma originates. This literature review is focused firstly on
melanocytes, describing their development, function, key regulatory mechanisms,
and the involvement of PAX3 in these processes. The review then focuses on
melanoma and on PAX3‐regulated pathways driving its development and
progression.
1.

Melanocytes: Development and function

Melanocytes are specialised pigment producing cells located in the skin, brain,
inner ear and choroid layer of the eye (pigmented cells in the retinal pigmented
epithelium are not of neural crest origin, rather they develop from locally derived
neural epithelium of the optic cup) [35]. Human melanocytes of the skin are
located in the hair follicles (termed follicular melanocytes) and at the epidermal‐
dermal border, above the basal lamina (termed interfollicular or epidermal
melanocytes). In contrast, mouse melanocytes are generally located in the hair
follicles, except for the hairless parts of the body (tail, nose and ears) where they
are located in the epidermis [36].
1.1. Melanocyte development: From neural crest through melanoblasts to
melanocytes
Melanocytic origin and embryonic development
Melanocytes originate from the neural crest in early developing embryos. The
neural crest is an ectodermal derivative of vertebrate embryos, which produces a
transient population of multipotent progenitor cells (Figure 1.1.1.A). These cells
arise at the lateral edge of the neural plate, adjacent to the non‐neural ectoderm,
and following the closure of the neural tube, they become located on the dorsal
side of the neural tube. After delamination and migration from the
neuroepithelium, these progenitor cells differentiate, committing to several
4
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lineages, including melanocytes, neurons, bone and endocrine cells, smooth
muscles and craniofacial cartilage (Figure 1.1.1.B) [37,38].

Figure 1.1.1. Neural crest formation and diversification. A) Schematic representation
of the emergence of neural crest progenitors at the boundary between the neural plate
(np) and the non‐neural epidermis (epi). Following the closure of neural folds (nf), neural
crest cells become located at the top of the closed neural tube (nt), from where migrating
neural crest (nc) cells are observed. B) Diagram of various cell types arising from
multipotent neural crest progenitors (adapted from [38]).

A subset of neural crest cells (Pax3, Sox10 (SRY (sex determining region Y) box 10)‐
expressing cells) give rise to melanocyte precursors, termed melanoblasts, which
are firstly observed in the cells overlaying and lateral to the neural tube. These
cells are further characterised by expression of the melanoblast markers Kit (vkit
HardyZuckerman 4 feline sarcoma viral oncogene), Mitf (microphthalmia
associated transcription factor) and Dct (dopachrome tautomerase) [12,39‐43].
Melanoblasts expand/proliferate in the migration staging area, before entering the
dorsolateral pathway and start migrating towards the developing epidermis
[12,44,45]. Upon reaching their final destination in the skin, melanoblasts
differentiate into melanocytes, expressing Tyr (tyrosinase) and Tyrp1 (tyrosinase
related protein 1), marking the start of melanogenesis (melanin synthesis) [43]. In
prenatal skin, a proportion of melanoblasts become incorporated into developing
hair follicles, while others remain located at the border between the epidermis and
dermis; the latter are lost in murine postnatal skin [46‐48], whereas in human
skin they persists postnatally [17,49‐51].
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Regulation of melanocyte development: Role of Pax3 during embryogenesis
Pax3 is one of nine members of the paired box (Pax) family of transcription factors,
which have all been implicated in regulation of organogenesis and described as key
factors in stem cell maintenance during development and maturation (reviewed in
[52,53]). Pax3 is involved in development of the central and peripheral nervous
system, skeletal muscle and cardiac tissue, gastrointestinal enteric ganglia, and
skin melanocytes.
Pax3 is the first regulator of neural crest specification [10,11,54]. Its expression is
observed in precursor cells prior to neurulation [17]. During neurulation, Pax3
plays a crucial antiapoptotic role, regulating proper development and closure of
the neural tube, via inhibition of p53 (tumour protein p53)‐mediated apoptosis,
and activation of its targets, BAX (BCL2associated X protein) and HDM2 (Mdm2 p53
binding protein homologue) [55,56]. Here Pax3 is also crucial for proper migration
of cells, via direct regulation of transcription of both TGFα (transforming growth
factor α) and TGFβ (transforming growth factor β) [57,58]. TGFβ signalling
pathways are involved in remodelling of the extracellular matrix, and cell
cytoskeleton required for cellular migration [58‐61]. Mutations or knock out
models of either Pax3, p53 or TGFβ, result in neural tube defects, confirming that
Pax3‐mediated regulation of cell survival and migration are crucial at this stage of
development [55,62].
Following neural tube closure, expression of Pax3 continues in a number of
progenitor cells, including those in the dorsal root ganglion, in the cells entering
the migratory pathway in the dermomyotome, myoblasts, and in developing
melanoblasts throughout their development (Figure 1.1.2.) [17,63]. Pax3 is crucial
for melanoblast specification, being at the very pinnacle of the hierarchy of
melanocyte‐specific gene regulators, directly activating other key melanocytic
regulators, including Mitf [64,65]. Pax3 is also required for proliferation of
committed melanoblasts prior to their entry into the early migration staging area
[12]. By contrast, Mitf promotes melanoblast survival during and immediately
following migration from the dorsal neural tube to the migration staging area [12].
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Figure 1.1.2. Pax3 expression during embryonic development. Pax3 expression is
observed in premigratory and migratory neural crest cells, and developing
dermomyotome at E12, and in melanoblasts in developing skin at E13 of murine
development (adapted from [66]).

It is clear therefore, that during embryonic development of melanocytes, Pax3
functions to specify, maintain and expand progenitor cells during completion of the
morphogenic program, thus facilitating their proper migration at key points.
The central role of Pax3 in melanocyte differentiation
The regulation of differentiation is probably, thus far, the best described role of
Pax3 in melanocytes. Pax3 directly binds to the Mitf promoter and, in synergy with
Sox10, activates Mitf transcription [64,65,67]. On the other hand, Mitf is the key
melanogenic regulator, activating the complete melanogenic cascade, from the
melanogenic enzyme‐coding genes (such as Tyr, Tyrp1 and Tyrp2/Dct), to the
genes encoding the structural components of melanosomes (such as Pmel
(premelanosome protein, also known as PMEL17, gp100, or SILV) and Mlana
(melanA, also known as MART1)) (Figure 1.1.3.A) [68‐71]. Thus by activating Mitf,
Pax3 drives the cell along a differentiation pathway. At the same time, however, it
competes with Mitf for occupancy of the Dct promoter, repressing its transcription
and preventing terminal differentiation (Figure 1.1.3.B). Pax3 binding to the Dct
promoter is mediated by the Groucho co‐repressor (Grg4), which physically
interacts with both Pax3 and Lef (lymphoid enhancer‐binding factor 1); mutations
in the Lef binding site in the Dct promoter abolish Pax3‐mediated repression of Dct
[19]. Lef1 also acts synergistically with Mitf to activate the Dct promoter [72]. In
7
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the presence of nuclear β‐catenin, however, Grg4, and hence Pax3, are displaced
from the Dct promoter, allowing Mitf to bind to the response element within the
Dct promoter (common to both Pax3 and Mitf), initiating its transcription (Figure
1.1.3.C) [19].

Figure 1.1.3. Schematic representation of regulation of melanogenic gene
expression. A) Pax3 activates a cascade of melanocytic gene expression. B) Pax3
activates Mitf (in synergy with Sox10) and represses Dct transcription at the same time.
Wnt signalling abolishes Pax3 mediated repression of Dct. C) Pax3 binding to the Dct
promoter is mediated by formation of a Groucho/ Lef/Tcf complex while β‐catenin,
activated by Wnt signalling, can displace Pax3 from the complex (Adapted from [19])

Pax3 also directly binds to the promoter region of the melanogenic enzyme, Tyrp1
[73,74]. Pax3 can therefore regulate melanocyte differentiation both indirectly,
through Mitf, or directly by regulating Tyrp1 and Dct [75,76]. It is not certain
however whether these mechanisms act at all stages of melanocytic development,
or whether the latter mechanism is a common regulatory mechanism at all.
Nevertheless, it is clear that Pax3 determines melanocytic cell fate while keeping
the cell in an undifferentiated state, poised to differentiate in response to external
stimuli [52]. It is likely that Pax3 prevents premature differentiation of
melanoblasts during their migration, while contributing to their proliferation and
expansion. Less clear is the function of Pax3 in melanocytes once they reach the
skin.
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1.2. Melanocytes of the adult skin
Human skin melanocytes are located both in the hair follicles and at the epidermal‐
dermal boundary (Figure 1.1.4.). Interfollicular/ epidermal melanocytes are
lodged between basal cells, and form close relationships with epidermal
keratinocytes, to which they distribute melanin, giving skin its pigmentation.
Follicular melanocytes are located in the bulb of the hair follicle where they
contribute to pigmentation of the growing hair. These two melanocyte populations
are predominantly mature differentiated pigment‐producing cells.

Figure 1.1.4. Distribution of three distinct populations of melanocytic cells in human
skin. This diagram represents a simplified structure of human skin and associated hair
follicle. Two populations of mature differentiated melanocytes are located in the
epidermis and in the bulb of the hair follicle. Melanocyte stem cells are located in the bulge
region of the hair follicle (adapted from [77]).

Adult skin does however contain another population of melanocytic cells,
melanocyte stem cells, located in the lower permanent portion of the hair follicle,
just below the musculus arrector pili. This stem cell niche (called a ‘bulge’),
provides a reservoir of adult stem cells that give rise to new hair [78,79]. Bulge
melanocyte stem cells represent a pool of progenitor cells serving to repopulate
9
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lost melanocytes in the hair and presumably in the epidermis [77,80‐82].
Melanocyte stem cells are immature, slow cycling and self‐maintaining cells that
remain quiescent in the niche until appropriate external stimuli initiate their
proliferation, migration and differentiation [78].
Since the hair and hair follicle go through continuous cycles of loss and
regeneration (Figure 1.1.5.), so therefore do follicular melanocytes. During the
hair cycle, the upper portion of the hair follicle remains permanent (Figure 1.1.4.),
in contrast to the lower transient portion, which undergoes cyclical stages of hair
growth and loss. In the anagen phase, the newly formed hair shaft grows and hair
protrudes through the skin surface. Following this, during the destructive catagen
phase, the lower part of the follicle undergoes apoptosis. The dermal papilla is then
brought to rest below the bulge, and after the resting phase (telogen), a critical
threshold of activating factors is reached and the bulge stem cells become
activated to regrow the hair. During the subsequent early anagen phase, hair
follicle regeneration starts from the bulge area, followed by the downward growth
of the basal portion of the follicle to form the hair matrix. This is accompanied by
simultaneous formation of the new hair that grows upwards, finally protruding
through the epidermis.
Bulge melanocyte stem cells are activated at early anagen to divide and generate a
population of cells that remain in the bulge as stem cells as well as amplifying
progeny that extend towards follicular papilla [78]. These two populations become
segregated in the growing follicle and amplifying progeny localise to the hair
matrix, proliferate and mature into fully differentiated melanocytes which produce
melanin, transfer it to the hair keratinocytes and then die by apoptosis during
catagen [83].
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Figure 1.1.5. Schematic representation of the hair cycle. The figure shows successive
stages of the hair cycle: anagen, catagen and telogen. Sg is sebaceous glad, Ap is arrector
pilli muscle, Bg is bulge, Dp is dermal papilla, Hs is hair shaft, IRS is inner root sheath, ORS
is outer root sheath, CTS is connective tissue sheath (adapted from [84]).

1.3. Melanocyte function: Regulation of melanogenesis
The main function of melanocytes is pigment production (or melanogenesis),
providing photoprotection and thermoregulation, thus contributing to the skin’s
protective function as the body’s main barrier to the external environment. During
melanogenesis, the precursor tyrosine is initially converted into dopaquinone,
from which biosynthesis proceeds, via independent mechanisms, to produce two
forms of melanin pigment, pheomelanin and eumelanin (Figure 1.1.6.). Production
of pheomelanin is spontaneously initiated in the presence of cysteine, whereas
eumelanin synthesis (in the absence of cysteine) involves action of three main

11

Chapter I – Thesis Overview
melanocytic enzymes: tyrosinase (TYR), tyrosinase‐related protein‐1 (TYRP1) and
dopachrome tautomerase (DCT/TYRP2) [85,86].

Figure 1.1.6. Biochemistry of melanogenesis. When tyrosine is oxidized by tyrosinase,
dopaquinone is produced as the immediate product. From dopaquinone two different
reactions are possible, formation of eu‐ or pheomelanin. A) In the absence of cysteine,
dopaquinone undergoes the addition of the amino group giving cyclodopa
(leucodopachrome). The redox exchange between leucodopachrome and dopaquinone
then gives rise to dopachrome (and dopa). Dopachrome gradually decomposes to give
mostly DHI, and to a lesser extent DHICA. This latter process is catalysed by DCT. Finally,
these dihydroxyindoles are oxidized to eumelanin: DHI oxidizes spontaneously (or faster
with tyrosinase action); DHICA transformation is slower but needs TYRP1 catalysis. B) In
the presence of cysteine, dopaquinone rapidly reacts with cysteine to give 5‐S‐
cysteinyldopa and to a lesser extent 2‐S‐cysteinyldopa. Cysteinyldopas are then oxidized
to give benzothiazine intermediates and finally to produce pheomelanin (adapted from
[85]).

Melanogenesis takes place in the specialised melanocyte organelles known as
melanosomes [87], where the pigment is synthesised and “packaged”. The
melanosomes are then transported to the adjacent keratinocytes via dendritic
cytoplasmic extensions. Four morphologically distinctive stages are observed that
correlate with successive stages of melanosome ‘maturation’ and biogenesis:
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stages I and II are described as non‐pigmented immature pre‐melanosomes;
whereas stages III and IV melanosomes are capable of melanogenesis (Figure
1.1.7.) [88‐91].

Figure 1.1.7. Melanosome biogenesis, maturation and secretion. Melanosome stages I
through IV are indicated. Non‐pigmented stage I melanosomes contain the melanosomal
protein Pmel17 sorted into intralumenal vesicles, and MART1. Stage II melanosomes are
characterised by Pmel17 undergoing proteolytic cleavage, forming intralumenal fibrillar
striations. The melanogenic enzymes TYR and TYRP1 are delivered to preformed stage II
melanosomes from early endosomes or transport vesicles from Golgi complex which
marks transition into stage III (adapted from [91]).

Stage I melanosomes are vacuolar early endosomes. Premelanosome protein PMEL
plays an essential role in the structural organization of premelanosomes: in stage I
melanosomes it is sorted into intralumenal vesicles, and later it undergoes
proteolytic cleavage to generate intralumenal fibrils of stage II melanosomes
[89,92‐94]. Stage I melanosomes also contain MLANA, required for proper function
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of PMEL and melanosome maturation [95,96]. The melanogenic enzymes TYR and
TYRP1 are delivered to stage II melanosomes via secretory pathway from the Golgi
complex and early endosomes (Figure 1.1.7.) [88,89]. Here they initiate
melanogenesis and further maturation into stage III melanosomes, characterised
by melanin deposition onto internal striations. Finally, stage IV melanosomes are
fully mature melanised organelles.
Epidermal melanocytes and surrounding keratinocytes form a symbiotic functional
relationship, termed the epidermal‐melanin unit that consists of around 36
keratinocytes to each melanocyte [97,98]. The precise process of melanosomal
transfer from melanocyte dendrites into keratinocytes is not clear, but possible
mechanisms include: cytophagocytosis of dendrite tips by keratinocytes;
exocytosis of melanin from melanocytes followed by their uptake by keratinocytes
via phagocytosis; transfer via membrane‐bound vesicles; or direct fusion of plasma
membranes of the melanocyte and associated keratinocytes (Figure 1.1.7.) [99].
Once transferred from the melanocyte, melanin accumulates above the nuclei of
keratinocytes, where it serves to protect mitotic keratinocytes from the ionising
effects of UV irradiation [100]. This is achieved by scattering UV radiation or
absorbing it and converting it into heat, or by absorbing DNA damage‐causing free
radicals generated in the cytoplasm (reviewed in [101]. In the event of extreme or
repeated exposure to UV irradiation, increased synthesis of melanin is evident by
“tanning”. Complex signalling networks between keratinocytes, melanocytes and
skin fibroblasts maintain skin homeostasis, and in the case of increased UV
exposure result in an increase in melanogenesis as well as in the number and
dendricity of melanocytes [20,102,103].
Melanocyte signalling pathways
A very complex and meticulously coordinated network of signalling pathways is
involved in the regulation of the fate and function of adult epidermal melanocytes,
with some pathway components contributing to more than one regulation
pathway (reviewed in [36]). Keratinocytes have a significant effect on melanocyte
proliferation as well as on melanogenesis, being the cells that are in a direct
contact with the external environment, and thus mediating external environmental
14
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signals to melanocytes. Keratinocytes stimulate melanocytes via secretion of
mitogens and melanogens, such as α melanocyte‐stimulating hormone (αMSH),
adenocorticotropic hormone (ACTH), basic fibroblast growth factor (FGF), stem
cell factor (SCF), and endothelins (ETs) [36].
Melanogenic signals and their receptors (like MSH, ACTH/MC1R (melanocortin 1
receptor), ET/EDNRB (endothelin receptor type B), Wnt (wingless‐type MMTV
integration site family)/frizzled family receptor) converge mainly on MITF,
increasing its transcription and upregulation of pigmentation‐specific genes,
leading to increased melanogenesis. On the other hand mitogenic signals mediated
by their membrane‐bound receptors (like SCF/cKit, bFGF/FGFR, HGF (hepatocyte
growth factor)/c‐Met (met proto‐oncogene)) activate receptor tyrosine kinases,
and initiate a cascade of phosphorylation events involving cytoplasmic mitogen‐
activated protein kinases (MAPK) (reviewed in [36]).
Disruption in crucial signalling pathways regulating normal melanocyte function,
usually as a result of mutations in key genes involved in these pathways, is
strongly linked to melanoma‐genesis (reviewed in [104]). Some of these pathways,
relevant to this study, are described below.
Activation of MAPK (RAS‐RAF‐MER‐ERK) pathway in melanocytes results in
increased

proliferation,

phosphorylation

[77].

survival,
MITF

but

also

phosphorylation

in

posttranslational

stabilises

the

MITF

MITF‐p300

transactivation complex, enhancing its transcriptional activity on target genes,
further contributing to melanogenesis [105]. Disruption and constitutive activation
of this pathway, through activating BRAF (vraf murine sarcoma viral oncogene
homologue B1) or NRAS (neuroblastoma RAS viral oncogene homologue), or cKit
mutations is recognised in many melanomas [104,106].
Another signalling pathway important for melanocytes is the canonical Wnt
signalling pathway, acting through β‐catenin and LEF‐1/TCF. Wnt proteins bind to
receptor complexes, including Frizzled‐3 and co‐receptor LDL Related Proteins
(LRP5/6). The most proximal intracellular component in a cascade of activation is
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molecular adaptor dishevelled (dsh) which gets recruited to the macromolecular
complex containing adenomatous polyposis coli (APC) gene product, axin and
glycogene synthase kinase‐3β (GSK‐3β). The formation of the complex blocks the
phosphorylation of β‐catenin by GSK‐3β, which would target β‐catenin for
proteosome‐mediated degradation [107]. This results in translocation of
hypophosphorylated β‐catenin into the nucleus where it cooperates with LEF‐1 on
target gene promoters, such as Mitf or Dct, enhancing their transcription, thus
driving melanocyte differentiation and melanogenesis [19].
Two of the Wnt proteins that are also implicated in melanoma, Wnt1 and Wnt3a,
are found crucial for development of the melanoblast [108]. Wnt1 promotes
melanoblast precursor expansion or specification, and Wnt3a promotes
differentiation along the melanocytic lineage at the expense of other cell lineages
[109]. Both of these Wnt proteins are associated with key melanocytic regulators,
Pax3 and Mitf; Wnt1 expression is activated by Pax3 [110], whereas Wnt3a
activates Mitf [111]. In adult epidermal melanocytes, inhibition of Wnt signalling
by dickkopf homologue 1 (DKK1) secreted from fibroblasts in the dermis,
suppresses melanocyte density and differentiation [112].
The opposing signalling pathway to Wnt, in terms of its effect on melanocytes, is
TGFβ signalling. The TGFβ family of signalling molecules plays a role in regulation
of a multitude of cellular processes in both normal and cancer cells, including
wound healing, epithelial‐to‐mesenchymal transition (EMT), differentiation,
proliferation, and response to the immune system [113‐115]. Binding of one of the
three main isoforms of TGFβ (TGFβ1, 2 and 3) to a type I and II TGFβ receptor
complex, activates phosphorylation of the intracellular mediators SMAD family
members 2 and 3 (SMAD2/3), resulting in their translocation into the nucleus,
complexing with Smad4, and transcriptional activation/repression of target genes
[116].
TGFβ (both 1 and 2) signalling has been shown to exhibit a repressive effect on
both melanocyte differentiation and melanogenesis (via downregulation of MITF
and PAX3) and to play a major role in driving immaturity and quiescence of
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melanocyte stem cells in the bulge [20,117,118]. But TGFβ also inhibits melanocyte
proliferation and induces apoptosis [116,117]. In skin, under normal conditions,
secretion of TGFβ by keratinocytes inhibits proliferation of epidermal melanocytes,
via PAX3 suppression [20]. UV exposure of skin, however, induces downregulation
of TGFβ, followed by PAX3 upregulation, and increased melanocyte proliferation
and melanogenesis [20].
Secretion of TGFβ1 by proliferating normal melanocytes is found to be induced by
exogenous factors [119,120]. It is interesting that both TGFβ1 and TGFβ2 are
upregulated by PAX3 [58,121], and PAX3 itself is repressed by TGFβ1 [20],
suggesting a negative feedback mechanism, involving PAX3 and TGFβ, which keeps
melanocyte proliferation upon mitogenic stimulation under control [119]. A close
functional relationship between TGFβ2 and PAX3 is even more evident since they
share some common targets (such are MITF, hairy and enhancer of split 1 (HES1)
and SRY (sex determining region Y) box 9 (SOX9)), while having opposing effects on
their regulation [122,123].
In contrast to normal melanocytes, loss of responsiveness to TGFβ–induced growth
inhibition by melanoma cells is strongly linked to metastatic melanoma
progression [119,124,125]. It is interesting that TGFβ1 treatment in growth
inhibition‐resistant melanoma cells does not downregulate PAX3 expression, and
overexpression of PAX3 in TGFβ‐sensitive melanoma cells results in their
desensitisation [20], suggesting that resistance to TGFβ observed in some
melanoma cells might be PAX3‐mediated.
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2.

Melanoma

Melanoma is a highly metastatic tumour arising from cutaneous melanocytic cells.
Some melanomas retain the physical characteristics of melanocytes, namely
pigmentation, giving melanomas a highly pigmented phenotype; on the other hand
some melanomas lose this ability and are amelanotic. Melanomas are, in general,
significantly heterogeneous, in terms of cell morphology, level of pigmentation and
marker expression [29,126]. Melanoma cells are also highly resistant to drug
treatment by employing various mechanisms that confer multidrug resistance,
including controlled drug uptake and export via membrane transporter systems, as
well as drug trapping and export via melanosomes (Figure 1.2.1.) [127,128]. In
addition, melanomas show a higher propensity to metastasise, relative to other
skin cancers [129].

Figure 1.2.1. Drug resistance mechanisms in melanomas. Melanoma cells become
resistant to anticancer drugs by several sequentially occurring mechanisms. Initially drug
resistance occurs as a result of reduced drug influx (e.g., reduced endocytosis, reduced
activity of an importer, or increased energy‐dependent efflux). Once drugs enter cells, they
can be trapped in subcellular organelles, such as melanosomes or other vesicles, and
exported from cells by enhanced melanosome transfer mechanisms. I–IV refers to stage I–
IV melanosomes (adapted from [127]).

Morphologically, melanomas consist of atypical, rounded (epithelioid) or spindle
(lentiginous) shaped cells, which initially aggregate in the epidermis and form
‘nests’ or ‘branches’ above the basal membrane. Histologically, several stages of
melanoma development are evident, associated with worsening prognosis and
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decreasing patient survival [8]. At early stages, melanoma is constrained within the
epidermis. At this stage it is thought to have a low metastatic potential; with
complete surgical removal, 5‐year survival rates are high. As the tumour continues
to develop, cells penetrate the basal membrane, and continue to expand in the
dermis. The risk of metastasis gradually increases as the tumour invades deeper
into the dermis. Once the melanoma reaches the subcutaneous fat tissue, the risk
of metastasis is high and systemic metastases are likely to occur. Cells that are
shed from the primary lesion infiltrate the circulatory and lymphatic system, and
migrate to new sites where they adhere to the walls of the capillary and invade a
new organ. It has been reported that 3‐4 x 106 cells are shed daily, it is not known
however how many of these cells have metastatic potential [130]. At the secondary
site, micrometastases can survive for several years before they become
proliferative, stimulate angiogenesis, and begin to form a metastatic tumour [131].
Advanced stage melanomas are described by the presence of regional or distant
metastases.
Melanoma origin and progression
The precise origin of melanoma is still uncertain and the exact mechanism of its
development and progression remain to be elucidated. Several possibilities exist
which explain melanoma origin, from epidermal melanocytes, or alternatively from
melanocytic stem cells, or even from dermis‐derived stem cells, suggested to give
rise to epidermal melanocytes and potentially also to melanoma [132]. The
likelihood of melanomas arising from bulge melanocyte stem cells or even follicular
matrix melanocytes is low since most of the primary melanomas are observed at
the epidermal‐dermal junction. A more likely origin would be from epidermal
melanocytic cells, since the existence of interfollicular melanocyte stem cells have
not yet been confirmed [133].
Large numbers of melanomas, around 40%, are observed to arise from pre‐
existing precursor lesions [134]. A linear step‐wise model has been suggested to
explain melanoma progression from a melanocytic naevus through to a dysplastic
naevus, followed by radial and vertical growth phases, via clonal evolution and
acquisition of additional mutations (Figure 1.2.2) [104,106,135]. The majority of
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melanomas however arise de novo, and do not necessarily follow this model of
progression.

Figure 1.2.2. Schematic representation of the linear model of melanoma progression. This
diagram shows consecutive steps in melanoma progression, from (a) normal epidermal
melanocytes, (b) through the formation of naevi, (c) pagetoid spread of atypical cells in radial
growth phase, (d) to the vertical growth of the lesion and dermal invasion (Adapted from [136]).

According to the linear model, three major steps/events are required for
melanoma progression, including clonal expansion of cells harbouring initial
mutation/s, acquisition of additional mutations allowing cells to overcome
senescence, and finally acquisition of mutations which result in suppression of
apoptosis [104,106,137].
Initial mutations in melanocytes, such as activating mutations in BRAF, NRAS, or
KIT, or amplification of cyclin D1 (CCND1) or cyclindependant kinase 4 (CDK4),
result in their increased proliferation. Over‐activation of proliferative signals
(oncogenic stress) is known to trigger cellular senescence, and benign pigmented
moles/naevi can be described as a senescent, clonal proliferation of melanocytes
[104,106,137]. Additional mutations, such as inactivation of cyclin‐dependant
kinase inhibitor p16/ retinoblastoma protein (RB) pathways or activation of
telomerase, are required to enable cells to overcome senescence and to become
proliferative and immortalised [104,106].
Lesions with changes described above, are early malignant melanocytic lesions,
known as superficial spreading melanomas. Melanoma cells at this stage are still
dependant on keratinocytes and their signalling network for maintaining survival
and can only proliferate close to the epidermis. This is described as the radial
growth phase (RGP) of melanoma. Additional changes are required to allow
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melanoma cells to escape keratinocyte dependence and invade deeper layers of the
skin, a stage that characterises the vertical growth phase (VGP) of melanoma
progression. This stage requires mutations that actively suppress apoptosis.
Genetic alterations consistent with advanced melanomas include loss of
phosphatase and tensin homolog (PTEN) (which inhibits apoptosis by
serine/threonin protein kinase AKT activation), RAS and RAF activating mutations
and β‐catenin activation [106,138].
Changes also occur in a network of cell adhesion molecules that enable melanoma
cell detachment. These include loss of E‐Cadherin, essential for melanocyte
homeostasis [139], and upregulation of N‐Cadherin which mediates gap junctions
with N‐cadherin‐expressing dermal fibroblasts [140]. Further changes that affect
basal membrane integrity include upregulation of matrix metalloproteinase‐2 that
enables invasion of the deeper layers [141]. Additionally, dermal invasion
correlates with the production of immune modifying factors such as interleukins,
chemokines and TGFβ [125]. Finally, vascularisation and melanoma growth, seen
at later metastatic stages, are regulated by several factors including connective
tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), basic
fibroblast growth factor (bFGF) and platelet‐derived growth factor (PDGF) [142].
An alternative to the linear progression model, is the melanoma ‘stem cell’ model,
in which progression towards a metastatic fate is driven by melanoma stem‐like
cells, as observed in other cancers [143‐147]. According to this model tumours
contain two distinctive cell subpopulations: one slow cycling population, that
resembles normal stem cells in terms of ability to self‐renew and give rise to a
differentiating progeny, carry tumourigenic potential; and another that derives
from these tumourigenic cells, has higher proliferative potential (maybe limited),
but will not seed new tumours. Further research suggests that the two
subpopulations of melanoma cells, with stem‐like and more differentiated
proliferative phenotype, are only temporarily distinct and that these phenotypes
are actually interchangeable [124,148].
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Interestingly, microarray analysis has identified two clearly distinguishable gene‐
expression profiles corresponding to the phenotype of two melanoma cell
subpopulations: one population of proliferative, more differentiated, weakly
metastatic cells which show a Wnt‐signalling gene expression signature, reflected
through upregulation of MITF and its downstream melanogenic targets; and a less
differentiated/stem‐like, highly motile aggressive population of cells, which show
upregulation of TGFβ‐signalling genes, involved in modifying the extracellular
environment [124,125]. Induction of TGFβ‐like signalling in melanoma, inhibits
Wnt signalling by driving the expression of Wnt‐inhibitor factors, thus leading to
less proliferative but more metastatic melanoma cells. This scenario is reminiscent
of normal melanocyte stem cells, residing in the bulge that is a Wnt–protected
area, lacking MITF and other melanogenic markers, in contrast to their
differentiating progeny in the Wnt‐responsive hair follicle [118,149,150].
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3.

PAX3 expression in melanoma and other neural crest derived
malignancies

The involvement of PAX proteins in cancer is well known [14,15,53]. A multitude
of studies consistently show PAX3 expression in melanoma [21‐26,73,151].
Research from our own lab, shows PAX3 in peripheral blood of melanoma patients
at various stages of melanoma, including many years after removal of the primary
lesion [152].
In addition to melanoma, PAX3 has also been found in tumours arising from other
neural crest‐derived tissues, such as classic medulloblastoma, benign peripheral
glial tumour neurofibroma (precursor of malignant nerve sheath tumour), Erwin’s
sarcoma, and supratentorial primitive neuroectodermal tumour [17]. PAX3 is also
know to be associated with paediatric alveolar rhabdomyosarcoma (ARMS), which
is caused by the gene fusion resulting from the t(2;13)(q35;q14) translocation
which juxtaposed the PAX3 (or its analogous counterpart PAX7, t(1;13)(p36;q14))
N‐terminus to the C‐terminus of the Forkhead (FKHD) transcription factor
[53,153‐156].
Several studies have identified PAX3 as an immunogenic protein in melanoma,
with several epitopes known to induce the host immune response [157‐159].
Experimental stimulation of the immune response against PAX3‐expressing
tumour cells resulted in melanoma growth suppression and increased apoptosis
[157,159]. In addition, inhibition of PAX3 expression by siRNA causes apoptosis in
both paediatric rhabdomyosarcoma and melanoma cells [25,28,155,156,160‐162].
All of this evidence highlights the importance of PAX3 in tumourigenesis, clearly
supporting its role in anti‐apoptosis. It is not clear however if this is the main or
only role for PAX3 in melanoma. Given the importance of PAX3 during embryonic
development and suggested role in tumour progression, the possibility that PAX3
plays additional roles in tumourigenesis required further exploration.
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iii.

SUMMARY

Many expression studies provide strong support for PAX3 involvement in
melanoma‐genesis, from the primary lesion, through circulating melanoma cells, to
metastatic melanoma [21‐26,73,151]. The suggestion that melanoma progression
might be driven by melanoma cells showing less differentiated stem‐like
phenotype [124,144,147], and the crucial roles that PAX3 plays in regulation of
melanocyte stem cells during development, implies that it might replicate these
roles in melanoma. The analogy between developmental processes and tumour
progression, such as delamination from the site of origin, migration through
tissues and adhesion at secondary sites, provide further support for this
hypothesis. Moreover, PAX3 is shown to be a nodal point in melanocyte
differentiation, since it simultaneously functions to initiate the melanogenic
cascade while preventing terminal differentiation, thus keeping the cell in a lineage
restricted stem cell‐like state [19].
Its expression in adult epidermal melanocytes has been uncertain, with only a few
studies reporting PAX3 expression in human melanocytes [16,17]. It has been
suggested that TGFβ‐mediated PAX3 upregulation under increased UV exposure
induces melanocyte proliferation [20]. Similarly, ectopic expression of PAX3
promotes growth, proliferation and migration of transfected melanocytes [163].
Taken together, the results highlight the importance of PAX3 in melanocytes, and
justify the need to identify the precise mechanism of its regulation, not just in
melanocytes but also in melanoma.
Normal skin melanocytes reside in a very dynamic microenvironment; on one side
they are exposed to the outer macroenvironment, and on the inside to a continuum
of cyclical changes. They have a close functional relationship with surrounding
cells, regulated by cell‐cell cross talk, to maintain homeostasis.
It is clear then that melanocytes are required to consistently maintain
responsiveness to environmental cues. This includes cyclic melanocyte stem cell
activation to proliferate giving rise to transient amplifying progeny cells that
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migrate in the growing hair towards the matrix of the bulb, where the mature
melanocytes will commence melanogenesis. Different signalling networks exist in
the niche (Wnt protected area) to that in the growing hair follicle [118,149,150].
Once the progenitor cells exit the niche, further signals determine their migration
and

maturation.

So

here,

melanocyte

stem

cell

progeny

respond

to

endogenous/intrinsic/ innate cycles dictated by the environment.
By contrast, epidermal melanocyte response is driven by exogenous/external
signals, predominantly UV exposure (reviewed in [164]. As a result, melanocytes
respond, by increasing in number and with increased melanogenesis [20]. It is not
clear however, whether increases in epidermal melanocyte numbers result from
their proliferation or from the activation and migration of bulge melanocyte stem
cells. A different mechanism to that of UV induced melanocyto‐genesis seems to be
employed in wound healing and in epidermal repigmentation in the case of vitiligo,
where newly formed melanocytes originate from the hair follicle [80,82,165‐167].
Those processes are clearly driven, in both of these situations, by the loss of local
epidermal melanocytes, and only melanocytic bulge cells are available for
repopulation of the epidermis.
In summary, normal melanocytic cells have an in‐built capacity to proliferate and
migrate when required. Since PAX3 is one of the key regulators of melanocyte
proliferation and migration during embryonic development, it is likely that its role
is maintained in melanocytes of the adult skin.
Moreover, it is not known whether the same developmental processes are likely to
be employed in melanoma development and progression. Initially malignant cells
proliferate intensively, resulting in growth of the primary lesion. Some of these
cells will be undifferentiated stem‐like cells, being able to self‐renew as well as
produce progeny able to differentiate. Eventually, some of the melanoma cells will
pass the basal membrane and invade the deeper layers of the dermis. This step
requires cells to be able to actively migrate, modify their immediate surrounding,
intercellular matrix, and survive independently of keratinocytes. Again, highly
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motile melanoma cells will migrate into the circulation and spread to distal
locations where they can generate metastases.
Given that PAX3 is a key regulator of these crucial cellular processes of
differentiation,

proliferation,

survival

and

migration

during

melanocyte

development, it may regulate similar processes in normal melanocytes,
predisposing them to malignant transformation. Similarly, it might regulate these
same processes in melanoma, given its high expression here, driving its
progression.
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iv.

RESEARCH DESIGN, HYPOTHESIS AND AIMS

Evidence supports a key role for PAX3 in melanocyte development during
embryogenesis, regulating cellular processes such as differentiation, survival,
proliferation and migration [10‐12,14,15,19]. It is also known that PAX3 is highly
expressed in melanoma [23‐25,168]. The continued PAX3 expression in
postnatal/adult melanocytes, however, requires confirmation [16,17].
If PAX3 is indeed continuously expressed throughout melanocyte cell maturation
the following question then remains: what is the role of this developmental
regulator in adult differentiated cells? The logical assumption is that the roles
would be similar to those of development. In addition, can it be assumed that the
roles of PAX3 in melanoma are similar to those in melanoblasts and melanocytes,
and if this is correct, does the mere presence of PAX3 in normal melanocytes
predispose them to a ‘plastic’ state that increases their tumourigenic potential and
then to a more aggressive phenotype upon malignant transformation?
Evidence suggests that at least some aspects of developmental PAX3 regulation are
active in adult melanocytes and melanoma cells. When PAX3 is transfected into a
nontumourigenic mouse melanocyte cell line, it increases proliferation and
migration [163], and inhibition of PAX3 results in melanoma growth suppression
and increased apoptosis [28]. These results support PAX3 involvement in the
regulation of melanocyte proliferation and migration, and similarly in regulation of
melanoma cell proliferation and survival. A key role of PAX3 in development is in
maintenance of an undifferentiated state, and it may be that PAX3 continues to
perform this role in adult melanocytes, so they remain ‘plastic’ and responsive to
environmental cues. Moreover, PAX3 may regulate survival and maintenance of
melanoma stem‐like cells, allowing their proliferation and migration. In this case
PAX3 might play an active role in melanoma‐genesis and metastasis.
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Hypothesis: Given the persistent expression of PAX3 in cells of the melanocytic
lineage, from the very precursor melanoblast cells of the developing embryo, to
postnatal melanocytes, and finally throughout the progression of melanocytic
lesions, we hypothesise that PAX3 is the key regulator of similar cellular processes
in both normal melanocytes and melanoma cell as observed in developing
melanoblasts. We also hypothesise that by regulating the ‘plasticity’ of melanocytic
cells, PAX3 enhances their tumourigenic potential and increases the aggressive
phenotype of melanoma cells upon malignant transformation, thus contributing to
melanoma progression.
The primary aim of this project is to identify the role of the PAX3 in melanocytes
and melanoma cells.
Specific aims:
1. To compare the functions of PAX3 in melanoblasts, melanocytes and
melanoma cells.
2. To assess PAX3 expression in normal skin and in a variety of melanocytic
lesions (including benign naevi and malignant melanomas), and to
characterise PAX3‐expressing cells with respect to markers of differentiation,
proliferation, survival and migration.
3. To identify the roles of PAX3 by analysis of its target genes in melanocytes
and in melanoma cells.
Aim 1: To compare the functions of PAX3 in melanoblasts, melanocytes and
melanoma cells.
To address this aim, an intensive literature search was performed to identify the
known roles for PAX3 during melanocyte development and melanoma‐genesis.
The outcome of this study was an all encompassing view of the role of PAX3 in
melanoma progression, published in Medic and Ziman, 2009, the first publication
towards this thesis (Chapter II).
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Aim 2: To assess PAX3 expression in normal skin and in a variety of
melanocytic lesions, and characterise PAX3expressing cells with
respect to markers of differentiation, proliferation, survival and
migration.
To achieve this aim, PAX3 expression was assessed in various tissue samples,
including normal skin, naevi and melanoma (in situ, invasive, systemic and lymph
node metastases). PAX3 expression across the variety of samples was analysed by
immunohistochemistry, and by quantitative RT‐PCR.
To characterise PAX3‐expressing cells, we initially performed co‐expression
analysis of PAX3 with a known melanocytic marker MITF to confirm that PAX3‐
positive cells were indeed melanocytic cells. Immunofluorescent double‐staining
was then used to further characterise the differentiation status of these cells.
Based on the known PAX3‐regulated pathways involved in normal melanocyte
development and differentiation, the following markers were used here to more
precisely determine the differentiation status of the cells: HES1 (marker of less
differentiated melanocytic cells), and MLANA (marker of differentiated
melanocytes).
Previous studies have implicated PAX3 in regulation of melanoma proliferation,
survival and migration, providing us with an array of markers to use for further
characterisation of PAX3‐expressing cells in melanoma tissue. Markers used were
for: proliferation (Ki67), survival (BCL2L1), and migration (MCAM). Again co‐
expression of PAX3 with these markers was analysed by immunofluorescence. The
frequency of PAX3 co‐expression with each marker was quantified in normal skin,
in naevi, and in primary and metastatic melanoma samples.
The results of these experiments were published in Medic and Ziman, 2010, the
second publication towards this thesis (Chapter III).
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Aim 3: To identify the roles of PAX3 by analysis of its target genes in
melanocytes and in melanoma cells.
To clarify the roles of PAX3 in melanocytes and melanoma cells we sought to
identify its direct targets in both cells types. By investigating published literature
we made a selection of confirmed and potential PAX3 target genes. These genes are
representative of the specific PAX3‐dependant regulatory mechanisms involved in
differentiation, proliferation, cell survival and migration. ChIP‐qPCR assay was
used to analyse PAX3‐binding to the promoter of the selected genes in vitro, in a
metastatic melanoma cell line, and in primary neonatal melanocytes. By
investigating the difference/similarity in PAX3 binding to its targets between
melanocytes and melanoma cells, we were able to identify mechanisms exclusive
to melanoma cells, but also confirmed mechanisms of PAX3 regulation common to
both melanocytes and melanoma cells. Levels of expression of target genes were
quantified to substantiate these findings.
The results of these experiments were published in Medic et al., 2011, the third
publication towards this thesis (Chapter IV).
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Abstract
The PAX3 transcription factor is critical for the proper development of neural crest
lineages including melanocytes. These cells show continued PAX3 expression from
formation to differentiation. While many expression, misexpression and mutation
studies clarify the importance of PAX3 in melanocyte development, less well
understood, and more perplexing, is the continued PAX3 expression in the adult
skin. In this article we explore the multiple roles of PAX3 in melanocyte genesis,
and draw on evidence from expression in developing melanoblasts, adult
melanocytes and melanocyte stem cells. From this, we present a more
encompassing theory that PAX3 is a key regulator of the myriad steps in
melanocytic cell determination. These roles may be accomplished by differential
association with cofactors, via alternate transcripts or posttranslational protein
modification(s). In light of the plethora of information gleaned from development
we then consider its roles in melanoma and provide here a comprehensive
consideration of the significance of PAX3 expression in melanoma. PAX3 and Pax3
indicate human and mouse transcription factor respectively.
Key words: Pax genes; melanocytes; melanoblasts; melanocyte stem cells; MITF;
melanoma
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Introduction
Cutaneous Malignant Melanoma is the most aggressive form of skin cancer,
thought to be derived from cutaneous melanocytes. Its aggressiveness is attributed
to frequent metastasis and high drug resistance. Intensive research of the
mechanisms regulating melanoma tumourigenesis has included investigation of
the factors and pathways of normal melanocyte development and function. One
key factor is the developmental transcriptional regulator PAX3.
PAX3/Pax3 (PAX3 and Pax3 indicate human and mouse transcription factor
respectively) is a member of the Pax family of transcription factors which are
highly conserved throughout phylogeny. All play a crucial role in embryogenesis
but are also implicated in tumourigenesis (for reviews see [13,14,52,53,169‐171]).
Pax3 protein contains two DNA binding domains, a paired domain and a
homeodomain which can be utilised alone or in combination to bind downstream
target genes [76,172‐174]. In addition Pax3 contains a C‐terminal transcription
activation domain and an octapeptide [173,175,176]. The ability of Pax3 to employ
one or both DNA binding domains accounts for its ability to regulate a variety of
downstream targets. Moreover, a single Pax3 gene encodes multiple transcripts
produced by alternate splicing (Figure 2.1) [11,151,168,177]. The resultant protein
isoforms provide functional diversity for Pax3, as they differ in structure and
ultimately in activity of their paired, homeodomain and alternate transactivation
domains [177‐179].
Even though Pax3 is recognised as a key embryonic regulator of melanocyte
specification and development, its expression and function in differentiated
epidermal melanocytes of adult human skin is uncertain and its role in melanoma
remains unclear. By clarifying its functions during embryonic and adult
melanocyte development we provide insights into its roles in melanoma.
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Figure 2.1. Schematic representation of human PAX3 mRNA splice variants. (A)
shows the exons (E) (E1 to E9) and introns and their respective sizes. (B) shows the
structure of alternative transcripts a, b, c, d, e, g, and h. Filled boxes depict sequences
retained in mature mRNA, clear boxes represent sequences spliced out and patterned
boxes are non‐transcribed sequences; the vertical blue lines represent the transcription
start sites and the vertical red lines and asterisks (*) indicate the positions of the alternate
stop codons. This representation is based upon current information for human PAX3
mRNA available on NCBI (Evidence Viewer Tool).

Melanocyte development during embryogenesis
Mammalian skin melanocytes originate from neural crest cells formed early in
developing embryos. Neural crest cells are ectodermal derivatives characteristic of
vertebrate embryos and represent a transient population of multipotent
progenitor cells arising at the lateral edge of the neural plate adjacent to the non‐
neural ectoderm. After delamination and migration from the neuroepithelium,
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these cells differentiate and contribute to various tissues, such as pigment cells,
neurons, bone and endocrine cells, smooth muscles and craniofacial cartilage [37].
As the cells divide and migrate, multipotent neural crest cells acquire more
lineage‐specific phenotypes, including that of melanoblasts, which upon reaching
its destination in the epidermis terminally differentiate into melanocytes.
Pathways crucial for the regulation of melanocyte development have been detailed
in mouse studies. Key genes regulating these pathways are those encoding
transcription factors Pax3 (Paired box 3), Sox10 (Sry‐like HMG box 10) and Mitf
(Microphthalmia transcription factor) (Figure 2.2A). Pax3 is first expressed in
neural crest precursors as they differentiate from the neural ectoderm [10,54];
expression continues as melanoblasts develop and migrate from the neural crest
and persists in these cells in developing hair follicles [63]. Similar temporal
expression is observed for Sox10, an early neural crest marker essential for the
survival of undifferentiated neural crest cells [180].
Specification along the melanocyte lineage, first observed in neural crest cells
overlaying and lateral to the neural tube at E10‐10.5, is denoted by the expression
of melanoblast markers Mitf, Kit (Kit oncogene) and Dct (Dopachrome
Tautomerase) [12,39‐43]. The melanoblasts expand a few hours later in the
migration staging area from where they enter the dorsolateral pathway and
migrate to the epidermis (E12.5‐E13.5) [44,45,63]. Once in the epidermis,
melanoblasts are incorporated into developing hair follicles and begin to express
Tyr

(Tyrosinase)

and

TRP1

(Tyrosine

related

protein1)

(E14.5)

[43].

Melanogenesis marks the emergence of differentiated melanocytes (E16.5) [43].
Melanoblasts migrate to the epidermis and in humans differentiate into
melanocytes which lie at the epidermal/dermal border [17,49‐51], whereas in
mouse these die off [46‐48]. Melanocytes also populate the hair follicle matrix in
both mouse and humans. These melanocytes show a molecular expression profile
characteristic of maturing melanocytes, expressing Pax3, Sox10, Mitf, Kit, Dct, Tyr,
TRP1 and SILV [150].
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Figure 2.2. Gene expression patterns in murine melanocytes during development. (A)
represents temporal expression of the crucial genes during sequential stages of embryonic
melanocyte development. (B) represents the hierarchy of melanocyte‐specific gene
activation.

Key factors in melanocyte development
Pax3, also known as MSF (melanocyte specific factor) [73], is one of the earliest
neural crest markers. It is expressed in neural crest precursors during neurulation,
and later in the dorsal neural tube, dorsal root ganglion (DRG) and in cells entering
the migration pathway in the dermomyotome [17]. Pax3 is crucial for neural crest
specification [10,11], and later for expansion of committed melanoblasts formed
early in development [12]. Mice that are homozygous for a mutation in Pax3 show
greatly reduced numbers of melanoblasts but the cells are able to migrate to
characteristic locations along the migratory pathway [12], suggesting a role in
specification and proliferation of melanoblast precursors but not in the migration
process, at least at this stage of melanoblast/melanocyte development.

36

Chapter II – Medic and Ziman, 2009
Sox10 is a transcription factor critical for the survival of neural crest cell
progenitors and proper differentiation of melanocytes [180]. Mice that are
homozygous for a mutation in Sox10, lack Mitf‐ and Dct‐expressing cells and have
reduced numbers of Kit‐expressing cells, due to the essential role that Sox10 plays
in activating the promoters of these genes [64,181,182].
Both Pax3 and Sox10 are required, and precede expression of the transcriptional
regulator Mitf [64,65,181]. Mitf is crucial for melanoblast survival during and
immediately following migration from the dorsal neural tube to the migration
staging area; mice that are heterozygous for a mutation in the Mitf gene show
diminished numbers of melanoblasts but only in early stages of development,
whereas during the migratory phase this number increases rapidly. Mitfmi/Mitfmi
mutant melanoblasts do not undergo dorsolateral migration (either they are not
capable of migration or they don’t survive) [12]. Mitf also has a role in melanocyte
stem cell survival in adult tissue, since mice homozygous for Mitfmivit (vitiligo
spontaneous mutation) exhibit vitiligo, characterised by initially normal
pigmentation which is lost during the next hair follicle cycle [183,184].
Dct encodes a melanogenic enzyme which marks the emergence of early
melanoblasts. Several transcription factors are involved in the regulation of Dct
expression including Pax3, Sox10, Mitf and Lef1 which all bind directly to the Dct
promoter and act together to activate transcription [19,72,185,186]. The Dct
promoter region contains an Mitf binding site (M‐box) directly adjacent to
upstream Lef1 binding sites [19,185,187]; Mitf and Lef1 act in synergy to activate
the Dct promoter [72]. Pax3 and Mitf share the same binding site within the Dct
promoter, and compete for occupancy [19].
In summary, the hierarchy of melanocyte‐specific gene activation (Figure 2.2B)
proposed by Opdecamp and colleagues (1997) suggests that in committed
melanoblasts, Pax3 and Sox10 synergistically induce Mitf expression. Mitf and
Sox10 then cooperate to immediately activate expression of Dct. Induction of Tyr
and TRP1 by Mitf follows a few days later. Expression of most of the melanogenic
enzyme genes, Tyr, TRP1 and Dct, as well as genes for melanosome biogenesis and
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melanin stabilisation, such as SILV and MelanA, begin in unpigmented
undifferentiated melanoblasts, where they show perinuclear localisation but
become cytoplasmic in fully matured melanocytes [188]. Unpigmented
differentiating melanoblasts possess early immature, stage I and II melanosomes
containing melanogenic enzymes [189]. Melanogenesis is however, a characteristic
of later stage III and IV melanosomes which with maturation take position at the
periphery of the cytoplasm [190].
Melanocyte stem cells in the adult skin
During embryonic development some melanoblasts will undergo transformation
towards quiescent cells and form a population of melanocyte stem cells remaining
in the bulge area of the hair follicles of adult mice and humans [48,191]. These
quiescent cells are characterised as being Dct‐ and Pax3‐positive [150].
Interestingly, other melanoblast markers expressed during embryogenesis, such as
Sox10 and Kit, are not detected in bulge melanocyte stem cells, suggesting different
mechanisms act to regulate production and maintenance of embryonal
melanoblasts and adult melanocyte stem cells.
Pax3, Sox10 and Mitf determine the balance between melanocyte differentiation
and maintenance of melanoblast and melanocyte stem cells in a process which is
dependent upon Wnt signalling [19,111]. The prerequisite for maintenance of
quiescent melanocyte stem cells is downregulation of the Wnt‐dependant
differentiation program. Indeed, the bulge area is described as a Wnt “protected”
area with increased expression of Wnt inhibitors such as Sfrp1, Dab2 and Dkk3 in
bulge cells [118,192]. These inhibitors decrease Wnt signalling as well as Mitf
levels [111], and as a result induce cell cycle exit [193] and melanocyte stem cell
quiescence.
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Multifunctional role of Pax3 during melanocyte development and maturation
Studies of temporal gene patterning of melanocytes in the developing embryo
indicate that although Pax3 is one of the first genes in the melanocyte specification
hierarchy, it clearly plays a much broader, multifunctional role during normal
melanocyte development (Figure 2.3). Here, we review the involvement of Pax3 in
differentiation, survival and migration of melanocytes. By analysis of Pax3 function
in normal melanocyte development we seek to gain not only a better
understanding of its involvement in adult differentiated melanocytes, but also a
greater appreciation of its role in melanoma, where it is commonly expressed.

Figure 2.3. Multiple roles of Pax3 in melanocyte development and maturation.
Schematic representation of the cooperation between Pax3 and other factors involved in
regulating “stemness”, differentiation, survival and migration.
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Pax3 and maintenance of the undifferentiated state
One of the best described roles for Pax3 is regulation of melanocyte differentiation;
as recently suggested it acts as a “switch” or a “nodal point” in differentiation of
these cells [19]. Pax3 is thought to activate melanocyte lineage specification but at
the same time it acts to block terminal differentiation, thus acting to maintain a
pool of undifferentiated melanoblast cells. A role in maintaining committed
progenitor cells is similarly observed in other Pax3‐dependant lineages, namely in
neuronal [122] and myogenic (reviewed in [15]) lineages. In regulating neuronal
precursors, Pax3 plays a dual role: at early stages of development it acts to
maintain “stemness” of migratory neural cells, via the repressor Hes1. Later it
initiates neuronal lineage specification via the proneural activator Ngn2 [122].
Hes1, is also implicated in maintenance of both embryonic melanoblasts and
melanocyte stem cells in the bulge area of adult mouse hair follicles, possibly via
Pax3 [194].
The pathways by which Pax3 maintains “stemness” have been detailed for
melanocyte stem cells of the bulge area of the adult mouse hair follicle. Pax3
inhibits differentiation by binding to the Dct promoter acting to repress Dct. Grg4
(Groucho co‐repressor) is also required for this interaction; it physically binds
both Pax3 and Lef1 to forms a complex on the Dct promoter. Lef1 is also a cofactor
for β‐catenin (activated by Wnt signalling), which displaces Grg4 together with
Pax3, allowing Mitf to bind to the response element within the Dct promoter. Pax3
has a higher affinity for the Dct promoter, thus replacing Mitf when present at
equal or higher concentrations [19]. Mitf binding to Dct and other genes encoding
enzymes for melanin synthesis Tyr, TRP1 initiates the melanogenic cascade. Thus
Pax3 acts as a molecular switch to direct this process by binding either to the Dct
promoter to inhibit differentiation or to the Mitf promoter in synergy with Sox10
to activate Mitf transcription [64,65,67] and the differentiation pathway.
In fact, Pax3 plays an even more complex role in regulation of melanocyte
differentiation; Pax3 also has the ability to directly bind to and positively regulate
the TRP1 promoter [73,74] thus enhancing the melanogenic cascade. In summary,
Pax3 interacts with distinct recognition motifs found in the promoters of MITF,
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TRP1 and Dct [75,76]. Notably, binding to the MITF promoter requires both the
paired and homeodomain of the Pax3 protein in contrast to the TRP1 and Dct
promoters where only the paired domain is required [76]. Different Pax3 isoforms
may mediate these different Pax3 binding activities [53].
As noted above, the role of Pax3 in melanocyte development is far broader than
just that of regulation of differentiation. Here we also describe the roles of Pax3 in
melanocyte survival, maintenance and migration ‐ roles that could implicate Pax3
in promotion of tumourigenesis and metastasis in melanoma.
Antiapoptotic role for Pax3
Mounting evidence supports an antiapoptotic role for Pax3. Several known
antiapoptotic factors, such as tumour suppressors p53, PTEN and Bcl‐Xl (see later),
are direct downstream targets of Pax3 or mediators of Pax3‐induced survival.
During embryogenesis, Pax3 regulates neural tube development via inhibition of
p53‐mediated apoptosis, keeping cells alive until the morphogenetic program is
completed [55]. A neural tube defect observed in Pax3deficient Splotch mice is
mediated in part by p53‐dependant apoptosis. Pax3 regulation of p53 may be via
alteration of protein levels, rather than transcriptional repression, since there are
no identifiable Pax3 binding sites in the promoter of the p53 gene [55].
Pax3 has a dual effect on p53: it represses transcription of p53‐dependant genes,
BAX and HDM2P2; and promotes p53 protein degradation [56,195]. p53 exhibits
its pro‐apoptotic function by promoting transcription of p21Cip/Waf1, cyclin‐
dependant kinase inhibitor, and members of the BH3 family of pro‐apoptotic genes
(BAX, PUMA and NOXA). In overexpression experiments, Pax3 suppresses p53‐
dependant activation of both BAX and HDM2 promoters, but not that of p21Cip/Waf1
[56]. In contrast, the Pax3 target, Mitf regulates p21Cip1 expression both directly
and

indirectly,

inducing

G1

arrest

[196].

Mitf

cooperates

with

the

hypophosphorylated form of Rb1, to activate p21Cip1 expression, which contributes
to cell cycle exit and activation of the differentiation program.
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PTEN expression is also directly inhibited by Pax3 [197], at least in myogenesis.
PTEN regulates progression through the G1 cell cycle check point, by negatively
regulating PI3K/AKT signalling, through cell cycle inhibitor (CDK inhibitor)
p27Kip1. Increased expression of Pax3 causes PTEN downregulation and a decrease
in apoptosis through the PTEN/AKT pathway, accompanied by downregulation of
p27Kip1 [197]. PTEN also directly regulates p53 activity [198,199].
Thus, the apparent antiapoptotic function described for Pax3, a function
presumably designed to facilitate migration of undifferentiated cells from the
neural crest to the epidermis, may in fact enhance the survival of melanoma cells.
Pax3 role in migration
Embryonic melanoblast migration is important for movement of cells from the
neural crest position to the epidermis. During embryogenesis Pax3 regulates
several genes that promote cell migration, including receptor tyrosine kinases; c‐
Ret during enteric ganglia formation [200,201], and cMet during limb muscle and
melanocyte development [121,202‐206].
Additionally, Pax3 directly represses expression of NCAM1 [173,207], a cell surface
molecule involved in cell‐cell adhesion. Pax3 also activates expression of STX,
which causes posttranslational polysialylation of NCAM preventing NCAM‐NCAM‐
mediated homophilic adhesion, leading to decreased cell adhesion and increased
migratory properties [204,208].
Other key genes involved in embryonic neural crest migration are TGFα and TGFβ
(reviewed in [209]), both of which are directly regulated by Pax3 [57,58]. TGFβ
signalling regulates genes responsible for remodelling the cell‐extracellular matrix
and adhesion molecule‐receptors and the cytoskeleton, thus playing a critical role
in the regulation of cell‐cell adhesion, growth, differentiation and migration [58].
TGFβ knock‐out mice show neural tube defects [62], and similarly Pax3‐deficient
Splotch mice show diminished levels of TGFβ and neural tube defects. Pax3 binds
to a cis‐regulatory element within the TGFβ promoter region, directly regulating its
transcription [58].
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Migration of melanoblasts is an important step in melanocyte development and
Pax3 appears to facilitate this process. Presumably, Pax3 is also important for the
movement of developing melanocytes form the bulge area to the matrix along the
hair shaft and into the epidermis. Moreover, migration and dissemination of
melanoma cells, a key factor in metastasis may indeed be PAX3 dependent.
Pax3 function in differentiated melanocytes
The wide spectrum of Pax3 functions performed at given points along the
developmental pathway may be operational in adult melanocytes and may in fact
continue in melanoma. Alternatively, Pax3 functions associated with embryonic
melanocyte genesis may differ from those of adult cells and melanoma cells, or
perhaps only a select few functions are activated in each of these cell types. In
melanocytes, Pax3 probably functions together with Sox10 in maintenance of
upregulation of Mitf and its downstream melanogenic genes to continually produce
melanin. Its role in maintenance of differentiated melanocytes remains to be
determined.
A key question that remains then is how are Pax3 functions regulated temporally?
Pax3 accomplishes specific temporal functions via interactions with several
specific cofactors present in a particular cell at any given stage of melanocyte
development [52,210]. Since Pax3 may have both activating and repressing roles in
transcriptional regulation [53,211], it might be that at one point in development it
is responsible for repressing and at another moment activating differentiation
processes, mediating and coordinating the cell fate in response to environmental
cues [52].
Changes in binding affinity and efficiency to downstream targets are important
determinants of Pax3 functional activity. In fact, in melanoblasts it preferentially
binds to the Dct promoter and blocks its activation by Mitf [19], but still retains
moderate activation of Mitf to maintain intermediate protein levels required for
melanoblast proliferation; it could also be involved in migration and survival of
undifferentiated committed melanoblasts. In melanocytes however, it shows
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preferential binding to both components of the differentiation pathway, i.e. MITF
and TRP1 [16], where it maintains melanocyte cell function. These results support
the idea that PAX3 has different role/s at different stages of melanocyte
development.
Regulation of Pax3 function
Another mechanism by which functional switching of Pax3 occurs is via
modulation of protein activity by cell cycle regulator pRB (retinoblastoma protein)
[212]. pRB family proteins have a dual role in both cell cycle regulation, and in cell
fate determination [212]. As a check point in the cell cycle, pRB acts as a negative
regulator by complexing with and inactivating E2F family members, repressing
their transcriptional function [213‐215] thus preventing cell cycle progression.
Secondly, as a determinant of cell fate, active unphosphorylated pRB forms a stable
complex with Pax3, repressing its transcriptional activity [212]. The implications
of this are that pRB repression of E2F transcriptional activity facilitates cell cycle
exit, and pRB repression of Pax3 transcriptional activity enables terminal
differentiation (by reducing levels of active Pax3 protein, thus allowing
accumulated Mitf to activate Dct expression and induce rapid terminal
differentiation) or apoptosis (due to an antiapoptotic role of Pax3). In other words
during cell proliferation active Pax3 protein levels are maintained. Upon exiting
the cell cycle however, Pax3 activity as an inhibitor of terminal differentiation is
suppressed, allowing the cell cycle to proceed.
Pax3 protein activity may also be regulated by phosphorylation and ubiquitination.
A Ser205 phosphorylation site has recently been identified; but to date
phosphorylated Pax3 has only been seen in proliferating mouse primary myoblasts
[216,217]. Pax3 protein stability is regulated by ubiquitination and proteasomal
degradation during adult muscle stem cell activation [218].
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Function determined by Pax3 levels
It is not certain how Pax3 protein levels determine its function(s). In neural crest
cells that are Pax3‐ and Sox10‐positive but Mitf‐negative, Pax3 expands the pool of
undifferentiated cells. Pax3 protein concentration (together with Sox10) may need
to reach a certain threshold in order to activate Mitf transcription and commit cells
to melanogenic lineage [73]. Indeed the amount of Pax3 protein appears to be a
key factor in determining its role in neural crest determination in developing
Xenopus embryos where different levels of Pax3 are required for activation of
different downstream targets. Intermediate doses induce Snail2 expression and
neural crest formation, and in high doses Pax3 strongly induces Xhe, thus changing
the cell fate towards that of a hatching gland cell [219].
Once Mitf is activated in melanoblasts it is possible that Pax3 function may be
driven, to some extent, by relative Mitf levels; Mitf needs to exceed a certain
threshold, much higher that the amount of Pax3, in order to drive the
differentiation pathway. In vitro experiments suggest that once the level of Mitf
reaches an amount significantly greater than that of Pax3 [19] repression of
differentiation is no longer possible and the melanogenic cascade is initiated.
Factors that upregulate Pax3 may also provide a clue as to its temporal functions.
Transcription factors NMyc and cMyc are both regulators of Pax3 transcription
[220]. Myc is actively transcribed in proliferating cells but very little is found in
senescent or differentiated cells. The cell cycle oscillation of Myc and Pax3 mRNA
levels was studied in cells in vitro; both are undetectable during starvation‐
induced growth arrest, but increase after addition of medium, yet decrease again
when cells enter S‐phase [220]. Peak Pax3 expression lags behind Myc by a couple
of hours, as expected for Myc‐regulated transcription of Pax3.
In turn, Pax3 itself represses the activity of cell cycle regulatory genes Rb, Myc, and
p21 by interacting with co‐repressor KAP1 [207]. Thus it appears that the levels of
Pax3 may be regulated via a negative feedback loop, since Myc upregulates Pax3
which subsequently downregulates Myc.
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Additionally, two POU transcription factors, Brn2 and Oct1, are positive Pax3
transcriptional regulators [221,222]. Bound as a monomer Brn‐2 has a positive
role in Pax3 expression in B16 (mouse melanoma cell line) cells, however when
bound as a homodimer it decreases Pax3 expression [223]. In vitro experiments
show BRN2 protein levels and DNA‐binding affinity decrease during melanocyte
differentiation [16]. By contrast, OCT1 levels increase during the differentiation
process [16] indicating that either BRN2 or OCT‐1 can regulate and maintain stable
PAX3 levels.
PAX3 expression in melanoma
While PAX3 function in developing melanocytes is reasonably clear, its precise role
in melanoma is undefined. Perplexingly, expression is observed in melanocytes of
normal skin [17]; our own unpublished observations), in benign naevi [24] and in
melanomas [21,23‐25,73,151]. In fact, PAX3 has been identified as a significant
marker for melanoma staging [22,26] and for detection of circulating melanoma
cells [22,224]. It has also been identified as an immunogenic protein in melanomas
[157‐159], with several epitopes able to induce the host’s immune response ‐
stimulation of the immune response against PAX3‐expressing tumour cells results
in tumour growth suppression [157,159]. Based on the information gleaned thus
far it is clear that the function of PAX3 in melanoma is more than merely a marker
of cell type.
PAX3 role(s) in melanoma
As in development, PAX3 plays an antiapoptotic role in cancers such as melanoma
and paediatric rhabdomyosarcoma [155,156,160‐162]. Transfection with PAX3‐
specific antisense nucleotide (PAX3‐As) induces increased cell detachment, growth
reduction and increased apoptosis in transfected melanoma cell lines [28]. PAX3‐
As‐transfected cells show increased numbers of p53‐positive cells, but no change
in TP53 mRNA levels, confirming that PAX3 regulation of p53 is posttranscriptional
[28].
46

Chapter II – Medic and Ziman, 2009

Additionally, inactivation of the tumour suppressor PTEN is often found in PAX3‐
positive human tumours and tumour cell lines, and its overexpression in tumours
results in cell cycle arrest and apoptosis via induction of p27Kip [225].
Transcription of BCLXL, a member of the BCL2 family of antiapoptotic genes, is
also directly regulated by PAX3 in rhabdomyosarcoma [226]. Treatment with PAX3
or BCLXL antisense oligonucleotides individually or in combination decreases cell
viability to a similar extent, suggesting that they lie in the same antiapoptotic
pathway [226]. Additionally, the PAX3 target MITF regulates BCL2 in melanocytes
and melanoma [227].
In a manner similar to its regulation of neural crest‐derived cell migration and
possibly melanocyte stem cells from the bulge area of the hair follicle, PAX3 may
facilitate dissemination of melanoma cells and metastatic progression. The
mechanism by which PAX3 may mediate melanoma metastasis is via regulation of
c‐Met, the HGF (hepatocyte growth factor) receptor involved in the regulation of
migration and cell motility in development. c‐Met transfection of immortalised
melanocytes resulted in their malignant transformation [203]. On the other hand,
overstimulation of HGF induces activation of the MAPK pathway and Mitf
phosphorylation which in turn induces recruitment of the transcriptional co‐
activator p300. This results in an increase in cMet mRNA and protein since c‐Met
is a direct transcriptional target of Mitf [228]. Thus PAX3 regulates c‐Met either
directly or indirectly via Mitf [121,228].
Opposing role(s) of PAX3 and MITF in melanoma
Recent microarray analysis of melanoma tissue was able to distinguish two
melanoma subgroups; one that is proliferative and weakly metastatic with a neural
crest‐like transcriptional signature maintained through Wnt signalling; the other
that is strongly metastatic showing upregulation of genes involved in modifying
the extracellular environment through TGFβ signalling [125,229]. Induction of
TGFβ‐like signalling in melanoma may inhibit Wnt signalling by activating the
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expression of Wnt‐inhibitors, leading to less proliferative but more metastatic
melanoma cells.
Given that microarray data reflect the profile of the majority of cells within the
tumour, it is possible that individual melanoma cells possess different metastatic
potential determined by their individual gene expression profile; more
differentiated melanoma cells expressing differentiation genes under Wnt
signalling would have low metastatic potential whereas less differentiated and
more stem cell‐like melanoma cells would have higher metastatic potential
regulated by TGFβ.
PAX3 is known to directly regulate TGFβ [58], whereas MITF is functionally
regulated by Wnt3a [111]. Interestingly, levels of MITF are an important
determinant of melanoma cell fate: depletion or complete loss of MITF results in
cell cycle arrest and/or apoptosis; increased expression levels favour
differentiation; and intermediate levels promote proliferation [193,227]. Indeed,
overexpression of Mitf in a highly aggressive melanoma cell line resulted in
morphological and behavioural changes towards a more differentiated and less
aggressive phenotype, evident by an increase in Tyr and TRP1 expression, as well
as an increase in p21 and p27 and arrest in G2/G1 cell cycle stage, together with a
decrease in Ki57 and an increase in Bcl‐2 [230]. Compared to the original cell line,
altered melanoma cells were less tumourigenic as evidenced by later development
of tumours and lack of liver metastases in injected mice.
PAX3 and MITF lie on the opposing sides of the differentiation regulation pathway,
determining less and more differentiated melanocytes respectively; similarly
perhaps they may dictate more or less differentiated melanoma cells that are more
or less metastatic. Intriguingly, MITF does not appear to be regulated by PAX3 in
melanoma, since PAX3 DNA‐binding to MITF promoter sequences is relatively less
efficient in melanoma cells than in melanocytes [16]. This suggests that in
melanocytic transformation, PAX3 is involved in some other aspects of melanoma
progression not MITF regulation.
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PAX3 and BRAFregulated pathways in melanoma
An additional mechanism by which PAX3 and MITF levels are regulated within the
tumour cells as via BRAF mediated pathways. One of the genes most frequently
mutated in both naevi and melanomas is the BRAF gene [231‐234]. Activating
BRAF mutations direct two downstream regulatory pathways: one stimulates the
Brn2 promoter, increasing its expression which drives Pax3 expression [222].
Interestingly, in a BRN2‐negative melanoma cell line, OCT‐1 levels are high,
whereas levels of OCT‐1 are low in a BRN2‐positive melanoma cell line [16]. This
may explain the persistent expression of PAX3 commonly observed in melanomas
[21,23‐25,73,151].
The second pathways activated by BRAF mutation is MEK‐ERK pathway which
leads to decrease MITF levels as a result of degradation of the MITF protein
[136,235]. This is evident since in tumours with MITF amplification, often seen
together with a BRAF mutation, the actual levels of MITF are not elevated
accordingly [136]. Interestingly, oncogenic BRAF exerts control over MITF on two
levels. It downregulates the protein by stimulating its degradation, but then
counteracts this by increasing transcription through BRN2. Thus oncogenic BRAF
plays a critical role in regulating MITF expression resulting in protein levels
compatible with proliferation and survival of melanoma cells [236].
Clearly, PAX3 and MITF levels are regulated independently and even
synonymously by numerous disregulated pathways in melanoma and together
these genes may contribute significantly to melanoma progression.
Isoform mediated roles
The myriad roles detailed for Pax3 may also be mediated by different isoforms
during both development and differentiation. A recent in vitro study detailed
transcript‐mediated growth characteristics in differentiated melanocytes [163]:
PAX3a, b or e transcripts showed decreased proliferation and migration; by
contrast PAX3c, d and h transfected melanocytes showed increased proliferation,
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migration and survival; PAX3g had no affect on melanocyte proliferation or
apoptosis, but reduced migration; and PAX3c, d, g and h isoforms were shown to be
associated with anchorage‐independent growth, conferring the ability of otherwise
anchorage‐dependant melanocytes to grow in soft‐agar [163].
It is interesting to note that PAX3c increases the migratory ability of transfected
melanocytes [163], and microarray analysis of PAX3c‐transfected cells show
upregulation of MCAM (also known as MUC18, and CD146) [121,204]. MCAM is
frequently upregulated in melanomas [229] and is associated with invasion and
metastasis [237].
Notably, expression of PAX3 isoforms varies in different PAX3‐associated cancers:
c and d isoforms are predominant in melanoma and small‐cell lung cancer
[158,168], and g and h in neuroblastoma [163]; a, b and e are expressed at low or
undetectable levels in all of the above tumours [163]. This suggests that full length
isoforms might promote tumourigenesis, whereas shortened isoforms might
repress tumour propagation. Indeed, microarray analysis showed downregulation
of PAX3a and PAX3b transcripts in aggressive melanomas compared to normal
melanocytes [238].
One explanation is that shortened PAX3 isoforms may compete with full‐length
isoforms and alter or inhibit their function [168]. Since PAX3a and b isoforms lack
a homeodomain theoretically they cannot bind Mitf, but may bind and induce TRP
1 [76] having an “immediate” effect on melanocyte differentiation. Thus the PAX3‐
induced migration, proliferation and survival of melanocytes may be mediated
either by MITF, or requires a fully functional homeodomain or a specific subset of
isoforms for activation of other target genes required for these processes.
Conclusion
Recently it has been proposed that melanoma, and tumours in general, contain
tumour “stem” cells harbouring metastatic potential [145,146,239‐242]. Given that
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[143,144,147,243] and since PAX3 is involved in maintenance of progenitor cells
[19,122,244], its role in melanoma may be similar, i.e. to maintain the melanoma
stem cell population. Further experiments to confirm this are underway.
Based upon the molecular signature of melanocyte stem cells in the bulge are of
the hair follicle ‐ i.e. positive for Pax3 and Wnt inhibitors, but negative for Mitf and
its downstream melanogenic targets [150] ‐ it seems likely that the melanoma
stem cells would have a similar signature. Indeed, melanoma stem cells are in fact
quiescent, slow growing, non‐melanised cells with a stem cell marker signature,
including ABCB5 [144,240].
Based on the information provided in this review, it is clear that the expression of
PAX3 in melanoma is much more than merely a marker of the cell lineage. It may
in fact be a key factor in determining melanoma cell fate as well as its migratory
properties, thus influencing its metastatic potential and ultimately the course of
the disease. Further research to clarify its specific role(s) in melanoma is required.
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Abstract
Background: Cutaneous Malignant Melanoma is an aggressive form of skin cancer,
arising in cutaneous melanocytes. The transcription factor PAX3 regulates
melanocyte specification from neural crest cells during development but
expression in differentiated melanocytes is uncertain. By contrast it is frequently
found in melanomas and naevi and is a marker for melanoma staging and
detection. In this study we analysed the expression of PAX3 across the spectrum of
melanocytic cells, from normal melanocytes to cells of benign and malignant
lesions to better assess its function in these various tissues. Pax3 and PAX3
(italicized) refer to the mouse and human gene, respectively; whereas Pax3 and
PAX3 (non‐italicized) refer to the corresponding mouse and human protein.
Methodology and Principal Findings: PAX3 expression was analysed by
immunohistochemistry and qRT‐PCR. Immunofluorescence was used for co‐
expression with differentiation, migration and survival markers. As expected PAX3
expression was observed in naevi and melanoma cells. It was also found in
melanocytes of normal skin where it coexpressed with melanocyte markers, MITF
and MLANA. Co‐expression with its downstream target, antiapoptotic factor
BCL2L1 confirms PAX3 as a cell survival regulator. PAX3 was also co‐expressed
with melanoma cell migration marker MCAM in dermal naevi and melanoma cell
nests, but this downstream target of PAX3 was not present in normal epidermal
melanocytes, suggesting differential roles for PAX3 in normal epidermal
melanocytes and melanoma cells. Most interestingly, a proportion of PAX3‐positive
epidermal melanocytes in normal skin show HES1 and Ki67 co‐expression,
indicating their less differentiated proliferative phenotype.
Conclusions and Significance: Our results suggest that a previously identified role
for PAX3, that of regulator of an undifferentiated plastic state, may operate in
melanocytes of normal skin. This role, possibly required for cellular response to
environmental stimuli, may contribute to formation and development of
melanocytic lesions in which PAX3 expression is prominent.
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Introduction
Cutaneous Malignant Melanoma is a highly aggressive form of skin cancer, thought
to be derived from cutaneous melanocytes or melanoblasts. Its aggressiveness is
attributed to frequent metastasis and high drug resistance. Intensive research into
the mechanisms regulating melanoma tumourigenesis has included investigation
of the factors and pathways of normal melanocyte development and function. One
key factor that regulates melanocyte development from neural crest derived
progenitor cells is the transcriptional factor PAX3.
PAX3 is very frequently expressed in melanomas and naevi [21,23‐25,73,151]. In
fact, PAX3 has been identified as a significant marker for melanoma staging [22,26]
and for detection of circulating melanoma cells [22]. It has also been identified as
an immunogenic protein in melanomas [157‐159], with several epitopes able to
induce the host’s immune response ‐ stimulation of the immune response against
PAX3‐expressing tumour cells results in tumour growth suppression [157,159].
PAX3 is a member of the PAX family of transcription factors which are highly
conserved throughout phylogeny. All play a crucial role in embryogenesis but are
also implicated in tumourigenesis [13‐15,52,53,169,209]. Although PAX3 is
recognised as a key embryonic regulator of melanocyte specification and
development, its expression and function in differentiated epidermal melanocytes
of adult human skin is largely unexplored and its role in melanoma remains
unclear [1].
Pax3 starts its expression in early embryos, in neural crest precursor cells that
later give rise to melanocyte precursors, melanoblasts [1,10,11,17,54,63]. Here the
main function of Pax3 besides neural crest specification is regulation of
melanoblast survival and proliferation [11,12]. Together with SRY (sex
determining region Y)‐box 10 (Sox10), Pax3 regulates expression of key
melanocyte specification factor Microphthalmiaassociated transcription factor
(Mitf). It has been suggested that Pax3 controls a “nodal point” in melanocyte
differentiation; it simultaneously activates Mitf and represses Dopachrome
54

Chapter III – Medic and Ziman, 2010
tautomerase (Dct) transcription thus blocking terminal differentiation [19]. Once
Mitf levels reach a certain threshold this repression is removed, allowing Mitf, in
the presence of β‐catenin, to activate Dct expression and melanocyte maturation.
This model of regulation of melanocyte differentiation suggests that Pax3
expression is either negligible or significantly reduced in adult differentiated
melanocytes.
Several studies report PAX3 expression in naevi and melanomas [21,23], and show
no expression in melanocytes of normal skin [24,25], thus concluding that PAX3 re‐
expression might be involved in melanocyte transformation. In contrast to this
widely accepted assumption, other studies note PAX3 expression in melanocytes of
normal skin [17,18], and more specifically its upregulation as a result of the UV‐
induced loss of TGFβ signalling from keratinocytes [20]. Additionally, PAX3
expression has been described in cultured melanocytes [16,73] and melanoblasts
with no significant change in levels of either mRNA or protein between these two
cell types [16].
Here we confirm that PAX3 is present in the majority of naevus and melanoma
cells. We also show conclusively that PAX3 is expressed in melanocytes of normal
skin where it is co‐expressed with known melanocyte markers. Since the precise
role played by PAX3 in melanomas is not clear, we have looked into potential PAX3
regulated pathways within normal melanocytes. We have chosen pathway‐
representative markers that are also downstream targets of PAX3 and analysed
their co‐expression with PAX3 in normal skin melanocytes, naevi and melanomas.
Interestingly, while the majority of PAX3‐positive melanocytes in the epidermis of
normal skin show a mature phenotype, a portion (around 20%) show a less
differentiated and proliferative phenotype. Moreover, PAX3‐positive melanocytes
frequently show expression of BCL2‐like 1 (BCL2L1, also known as Bcl‐X, bcl‐xL or
BCL‐XL/S), an antiapoptotic marker. Taken together these results indicate that
melanocytes of the normal skin display a phenotype that is predisposed to
malignant transformation (antiapoptotic, undifferentiated and proliferative). We
also show that PAX3‐positive epidermal melanocytes of normal skin are
molecularly distinct from those of the hair follicle, which like melanoma cells
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express Melanoma cell adhesion molecule (MCAM, also known as MUC18/CD146),
associated with cell migration and melanoma progression and metastasis.
Results
PAX3 expression in normal skin, naevi and melanoma
PAX3 expression was analysed by immunohistochemistry in tissue sections from
paraffin embedded samples of normal skin, naevus, primary melanoma and
melanoma metastases. Positive staining for PAX3 was obtained after performing
heat‐induced antigen retrieval in an EDTA/Tris buffer, pH 8.0 and incubating the
primary antibody (anti‐PAX3, DSHB) at room temperature (Figure 3.1A, top panel).
Antigen retrieval using the most common 10mM Citrate buffer, pH 6.0 with the
same staining protocol, failed to produce a positive signal in several of these
samples, and in those that were positive after citrate antigen retrieval, the
intensity of staining was dramatically reduced. Negative controls included omitting
the primary antibody from the procedure resulting in no immunohistochemical
signal (not shown). Mouse monoclonal anti‐PAX3 antibody (DSHB) has been
previously confirmed by immunohistochemistry to be specific to PAX3 protein
[245]. PAX3‐specific staining was also confirmed using a different commercially
available anti‐PAX3 antibody (Invitrogen) (Figure 3.2, A‐C and E). However, we
have observed less intensive staining overall with this polyclonal antibody
(Invitrogen) compared to that observed with the monoclonal (DSHB).
All of the samples analysed showed positive PAX3 staining in more than 10% of
cells (Figure 3.1A, top panel). In normal skin PAX3‐positive cells showed a pattern
of distribution that is characteristic of melanocytes; i.e. they were found at the
epidermal‐dermal boundary and along the hair follicle (Figure 3.1A‐D). When
adjacent sections were stained with MITF, a known marker of melanocytes, a
comparable pattern of distribution was observed (Figure 3.1A, bottom panel).
The intensity of PAX3 staining varied between cells within the same lesion and
between different samples. There was no obvious correlation between either
intensity or number of PAX3‐positive cells and lesion type. However, PAX3‐
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positive cells of normal skin samples generally showed weaker staining and far
fewer cells were positive, compared to those in naevi and primary melanoma
samples. In contrast, melanoma metastases have an overall low level of PAX3
expression and these cells were mainly located at the periphery of the lesion.
Additional analysis by quantitative RT‐PCR was performed on a separate set of
samples, to confirm PAX3 expression in normal skin, naevi, primary melanomas,
and melanoma metastases. PAX3 expression was detected in all naevi (5/5),
primary melanomas (5/5) and melanoma metastases analysed (5/5), and in one
out of two (1/2) normal skin samples. The highest levels of PAX3 expression were
found in melanoma metastases (mean fold change of 2583±1198), followed by
naevi and primary melanomas with 101±39 and 73±55‐ fold change, respectively
(Figure 3.1E). Even though these results suggest that PAX3 might be upregulated in
advanced melanomas (melanoma metastases vs. primary melanomas) comparison
with immunohistochemistry results show that expression levels are not due to
increased amounts of PAX3 per individual cell, but rather they reflect the number
of cells expressing PAX3 (Figure 3.1A). Nevertheless RT‐PCR results confirm PAX3
expression in melanocytes of normal skin.
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Figure 3.1. PAX3 expression in melanocytic and melanoma cells. A)
Immunohistochemistry shows PAX3 expression (top panel) in representative samples of
normal skin, naevus, primary melanoma and melanoma metastasis, compared to MITF
expression in adjacent sections (bottom panel). B‐D) Show the distribution of PAX3‐
positive melanocytes (arrowheads) in normal skin: along the hair follicle (early (B) and
late (C) anagen); and in the epidermis (D). Arrows in D point to the cytoplasmic melanin
deposit distinguishable from the nuclear PAX3 staining (arrowheads). Asterisk in (B) and
(C) marks a dermal papilla. PAX3 was labelled with mouse monoclonal antibody (DSHB).
E) PAX3 expression was analysed by RT‐PCR and the graph shows the mean fold increase
of PAX3 expression in naevi, primary melanomas and lymph node metastases normalised
to the expression in normal skin.
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Characterisation of PAX3positive cells: Coexpression of PAX3 and MITF
In order to validate PAX3 expression in naevi and melanomas as well as to confirm
that PAX3‐positive cells in normal skin are in fact melanocytes, co‐staining of PAX3
and MITF was assessed by immunofluorescence. Indeed, in all of the samples
analysed, including normal skin, PAX3‐positive cells co‐express MITF (Figure 3.2,
A‐C and E). However, in normal skin (as in other samples) a small number of cells
showed only MITF and not PAX3 expression, highlighting the variation in normal
epidermal melanocyte cell phenotype.
In normal skin samples 81.6% of all MITF‐positive melanocytes were also PAX3‐
positive (Figure 3.2D). Both naevi and primary melanoma samples show similar
numbers of MITF‐positive cells that also express PAX3 (97.2% and 94.5%,
respectively) (Figure 3.2D). Interestingly, melanoma metastases show significantly
less PAX3‐positive than MITF‐positive cells (Figure 3.2D), and generally these
were weakly stained for PAX3. However, this was observed primarily when using
rabbit polyclonal antibody to PAX3 (Invitrogen) for immunofluorescent staining.
When the mouse monoclonal anti‐PAX3 antibody (DSHB) was used for
immunohistochemistry staining, many more PAX3‐positive cells were observed on
the same sample. The discrepancy between these two results is probably due to
the sensitivity of the two antibodies. Nevertheless, the intensity of PAX3 staining
varied when either antibody was used, whereas MITF levels were uniform across
samples (Figure 3.2, A‐C). This is shown clearly in the A2058 metastatic cell line
(Figure 3.2C) and may also reflect different cell status/phenotype.
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Figure 3.2. Coexpression of PAX3 and MITF in melanocytic and melanoma cells. A‐
C) Double immunofluorescent staining showing co‐expression of PAX3 and MITF in: (A)
epidermal melanocytes of normal skin; (B) primary melanoma; and (C) in an A2058
metastatic melanoma cell line. Arrowheads in (A) show PAX3‐positive normal epidermal
melanocytes. Lines in (A) and (B) demarcate epidermal‐dermal border (EDB). The variable
PAX3 expression was clearly visible in A2058 cell line (C). For all these experiments
depicted in the figure, PAX3 was labelled with rabbit polyclonal antibody (Invitrogen). D)
Graph showing overall number of MITF and PAX3 double labelled cells in normal skins,
naevi, primary melanomas and melanoma metastases. Each column represents a
percentage of MITF‐positive cells that are also PAX3‐positive averaged across all samples.
E) Double immunofluorescent staining shows PAX3 and MITF co‐expressing melanocytes
(yellow‐orange) in the bulb of the hair follicle of normal skin. Note the single MITF‐
labelled melanocytes (green) at the base of the hair.
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PAX3 in melanocyte differentiation: Coexpression of PAX3 with MITF, HES1
and MLANA
Even though the overall percentage of MITF‐positive melanocytes that were also
PAX3‐positive in normal skin was not significantly different to either benign or
malignant melanocytic lesions (Figure 3.2D), the distribution of cells that co‐
expressed PAX3 and MITF differed between the epidermis and hair follicles of
normal skin. Around 90% of MITF‐positive melanocytes in the epidermis and the
outer root sheath (ORS) of the hair follicle were PAX3‐positive, compared to only
65% of those in the bulbar area (Figure 3.3D). Interestingly there was a distinct
location in the hair bulb, at the very base of the hair, populated exclusively by
MITF‐positive melanocytes (Figure 3.2E).
Given this difference between epidermal and follicular melanocytes, we thought it
necessary to further characterise PAX3‐positive melanocytes in the normal skin.
We therefore co‐stained PAX3 cells with Hairy and enhancer of split 1 (HES1)
(Figure 3.3A and 3.4A‐C) or Melan‐A (MLANA, also known as MART‐1) (Figure
3.3B and 3.4D, E), markers of less or more differentiated cell phenotype
respectively. Upon analysis of the distribution of double‐labelled cells we found
that HES1 was expressed in a proportion of PAX3‐positive melanocytes, while cells
that were only HES1‐positive were identified as keratinocytes [246,247] (Figure
3.3A). The number of PAX3‐positive melanocytes co‐expressing HES1 was lowest
in the matrix of the hair bulb (10.5%), compared to the ORS (23.7%) and the
epidermis (27.9%) (Figure 3.3D). By contrast, MLANA was expressed in more that
60% of both epidermal and ORS PAX3‐positive melanocytes, compared to 36% of
those in the matrix of the hair bulb (Figure 3.3D). We have also observed a
significant number of single MLANA‐labelled melanocytes (Figure 3.3B) (30.5% in
the epidermis, 3.9% in ORS, and 40% in the hair bulb).
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Figure 3.3. Coexpression analysis of PAX3expressing epidermal melanocytes of
normal skin. Epidermal melanocytes of normal skin show variable differentiation status:
less differentiated melanocytes co‐expressing PAX3 (mouse monoclonal antibody, DSHB)
and HES1 (A); more differentiated co‐expressing PAX3 (rabbit polyclonal, Invitrogen) and
MLANA (B); and mature melanocytes expressing only MLANA (B). Single HES1‐labbeled
cells in the epidermis are keratinocytes (A). C) PAX3 (mouse monoclonal antibody, DSHB)
and Ki67 co‐expressing melanocytes are also observed in the epidermis of the sun‐
exposed skin. Lines in (A), (B) and (C) demarcate epidermal‐dermal border (EDB) or
epidermal surface (ES). D) Graph shows the distribution of differentiation marker
expression in normal skin melanocytes with respect to melanocyte location (in epidermis,
outer root sheath (ORS), or hair follicle bulb).
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This indicates that melanocytes, both follicular and epidermal, have a variable
differentiation status: from less differentiated PAX3, MITF and HES1‐positive to
more differentiated PAX3, MITF and MLANA‐positive. The observed PAX3‐
negative, MLANA‐positive epidermal melanocytes may represent mature
terminally differentiated melanocytes.
In addition, Yang and colleagues [20] have recently proposed that in UV‐treated
skin TGF‐β signalling from keratinocytes is downregulated, which increases PAX3
expression in epidermal melanocytes and stimulates their proliferation. In order to
check if PAX3‐positive melanocytes observed here are proliferating we co‐stained
PAX3 with a marker of proliferation Ki67, and found 18.1% of epidermal
melanocytes in samples of sun‐exposed skin (scalp) to be double‐labelled (Figure
3.3C). In contrast to this, in samples that had relatively little sun exposure (breast)
one single double labelled cell was observed in the epidermis (accounting for 1.4%
of PAX3‐positive cells).
PAX3 in cell survival: Coexpression with BCL2L1
To further characterise the phenotype of PAX3‐positive melanocytes relative to
melanoma cells, expression of an antiapoptotic factor BCL2L1 was assessed in
PAX3‐positive cells (Figure 3.5A). We have observed that a similar proportion of
PAX3‐positive cells were also BCL2L1‐positive in melanocytes of normal skin, in
naevi and in melanoma cells in all of the samples analysed (Figure 3.5D). The
exception is melanoma metastases, in which BCL2L1 was detected in only one
sample (out of four) and both PAX3 and BCL2L1 were weakly stained and very
rarely co‐stain. BCL2L1 expression in epidermal keratinocytes, as reported
previously [248], served as an internal positive control for the staining.
BCL2L1 expression in normal PAX3‐positive melanocytes indicates that they might
utilise the same cell survival regulatory mechanism as melanoma cells, in order to
sustain continuous renewal in the ever‐changing environment of the epidermis. It
is possible that one of the roles PAX3 plays in adult melanocytes (similar to that in
development) is to ensure their maintenance and survival, while regulating their
specification and proliferation.
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Figure 3.4. Coexpression analysis of PAX3positive follicular melanocytes. A) The
transverse section of the hair follicle shows both PAX3 and HES1 co‐expressing (enlarged
in B), and single PAX3‐expressing (enlarged in C), melanocytes in the outer root sheath
(ORS). The line circumcises the hair follicle. PAX3 was labelled with mouse monoclonal
antibody (DSHB). D) The longitudinal section of the hair follicle shows PAX3 and MLANA
co‐expressing (enlarged in the insert on the left) and single PAX3‐expressing (enlarged in
the insert on the right) melanocytes in the outer root sheath (ORS). E) Single PAX3‐
expresing (arrows) and PAX3 and MLANA co‐expressing (arrowheads) melanocytes in the
matrix of the hair bulb. PAX3 was labelled with rabbit polyclonal antibody (Invitrogen).
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PAX3 in cell migration: Coexpression with MCAM
Expression of the melanoma progression marker MCAM was also analysed relative
to PAX3. MCAM expression was observed in most naevi and melanoma samples
analysed; 80% (4/5) naevi samples, 66.7% (4/6) primary melanomas and 100%
(5/5) of melanoma metastases. There was no MCAM expression in epidermal
melanocytes of normal skin (Figure 3.5B). Notably we frequently observed MCAM
expression in hair follicle cells of normal skin [192,249,250], mainly in the ORS and
not exclusively in melanocytic cells (Figure 3.5C). MCAM expression in the
endothelial cells of the blood vessels served as an internal positive control
[250,251].
In naevi samples MCAM expression was observed in specific areas, mainly in nests
of cells in the dermal component of the naevus and only a small proportion
(14.7%) of a PAX3‐positive cells were MCAM‐positive (Figure 3.5B, E). Compared
to naevi, primary melanomas showed MCAM expression in a larger proportion of
PAX3‐positive cells, 56.4% (Figure 3.5B, E), which are again primarily located in
the dermal component of the lesion. Samples of melanoma metastases showed
MCAM expression in the majority (93.2%) of PAX3‐positive cells (Figure 3.5B, E).
In general, MCAM co‐expressed with PAX3 in all MCAM‐positive samples. In
accordance with previous reports [249], number of MCAM expressing PAX3‐
positive cells increased with malignant and particularly metastatic transformation.
The expression of MCAM in follicular melanocytes, in contrast to the absence of
expression in epidermal melanocytes, highlights again the difference between
these two melanocyte populations.
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Figure 3.5. Coexpression of PAX3 with markers of cell survival and migration in
melanocytic and melanoma cells. A) Double immunofluorescent staining showing PAX3
(mouse monoclonal antibody, DSHB) and BCL2L1 co‐expression in representative samples
of normal skin, naevus, primary melanoma and melanoma metastasis. B) PAX3 (mouse
monoclonal antibody, DSHB) and MCAM co‐expression in normal skin (epidermal
melanocytes), naevus, primary melanoma and melanoma metastasis. Lines in (A) and (B)
demarcate epidermal‐dermal border (EDB) or epidermal surface (ES). C) In contrast to
the epidermal melanocytes, some PAX3‐positive melanocytes in the outer root sheath
(ORS) co‐express MCAM. D) Graph showing overall number of PAX3, BCL2L1 double‐
labelled cells in normal skins, naevi, primary melanomas and melanoma metastases. Each
column represents a percentage of PAX3‐positive cells that are also BCL2L1‐positive,
averaged across all samples. E) Graph showing overall number of PAX3, MCAM double‐
labelled cells in normal skins, naevi, primary melanomas and melanoma metastases. Each
column represents a percentage of PAX3‐positive cells that are also MCAM‐positive,
averaged across all samples.
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Discussion
PAX3 expression in normal skin, naevi and melanoma
In agreement with previous reports, we confirm here that PAX3 is expressed in all
melanoma and naevi samples analysed. There is however a paucity of studies
analysing PAX3 expression in differentiated melanocytes in human skin.
Traditionally considered a critical embryonic regulator, PAX3 has been suggested
to maintain melanocyte stem cells in the bulge area of the hair follicles in mice
[19], but was thought to be downregulated upon terminal differentiation of
melanocytes. This belief has been supported by reports detailing absence of PAX3
expression in melanocytes of normal human skin in contrast to naevi and
melanomas [24,25]. Our results show conclusively that PAX3 is expressed in both
epidermal and follicular melanocytes of human skin. Furthermore, co‐expression
with MITF confirms the melanocytic origin of these PAX3‐positive cells. We also
show here, for the first time, the variable phenotype of epidermal melanocytes of
normal skin.
The observed frequency of PAX3 expression in naevi, melanomas and specifically
in melanocytes in normal skin is much higher that reported elsewhere [24,25]. One
possible explanation could be the methodology we used, mainly EDTA/Tris
antigen retrieval buffer, rather than the citrate buffer commonly used by other
researchers, which was, in our experience, less efficient. It might also reflect the
influence of environmental factors, namely sun exposure and solar radiation. It has
recently been suggested that in UV‐treated skin TGF‐β signalling from
keratinocytes is downregulated, increasing PAX3 expression in epidermal
melanocytes thus stimulating their proliferation [20]. All the samples used in this
study are collected from people living in Australia, where the solar radiation levels
are in the high to extreme range for much of the year. A recent report from New
Zealand [18] shows PAX3 expression in all naevi, melanomas and normal skin
samples, confirming our findings. Further studies are required to investigate
differences in PAX3 expression in skin samples derived from the Southern vs. the
Northern hemisphere.
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Normal skin samples used in this study, mainly originating from anatomic
locations frequently exposed to the sun (such as limbs and face), were free of any
melanocytic lesion having been used for other diagnostic purposes. We have
included here two normal skin samples from breast reductions which would have
lower sun exposure levels and these samples also show PAX3‐positive melanocytes
in the epidermis. We have looked to see if PAX3‐positive melanocytes in our
samples were proliferative, by co‐staining with Ki67. In our samples of sun‐
exposed skin, 18.1% of epidermal PAX3‐positive melanocytes were proliferative,
but the majority were not. This was in contrast to samples subjected to low levels
of sun exposure, where we observed one single PAX3, Ki67‐positive cell. However,
to accurately address the question whether the high frequency of PAX3 expression
in normal melanocytes observed in this study, relative to previously published
papers, is caused in any way by the extent of sun exposure, a more thorough
analysis of skin subjected to chronic and/or acute UV exposure relative to sun‐
protected skin, would need to be performed.
PAX3 expression in melanocytes of normal adult skin: A role in regulating
differentiation?
PAX3 and MITF are crucial regulators of melanocyte development and not
surprisingly have overlapping expression. To some extent they lie on opposing
sides of the differentiation pathway, PAX3 being upstream of MITF and MITF
initiating the melanogenic cascade and differentiation. We were interested to see if
there is an association between expression of PAX3 and MITF (indicated by their
co‐expression) and the stage of melanocyte differentiation (based on the cell
location, mainly in the hair follicle), but found no correlation. Studies on mice and
human skin both show the existence of skin stem cells in the lower permanent
portion of the hair follicle, or bulge [78,192,252]. It is reported that mouse bulge
melanocyte stem cells are PAX3‐positive and MITF‐negative [150]; however no
reports confirm this to be the case in human skin. In this study we were not able to
find such cells. Instead the majority of melanocytes we observed, both in the
epidermis and the outer root sheath of the hair follicle, were PAX3 and MITF‐
positive. In contrast to this, the matrix of the hair bulb has far fewer PAX3 and
MITF‐positive melanocytes and the base of the hair comprises solely MITF‐positive
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(PAX3‐negative) melanocytes. Similarly, the number of PAX3, MLANA‐double‐
labelled melanocytes in the epidermis and ORS were around 60%, but were much
lower (around 36%) in the hair matrix. This would indicate that some epidermal
melanocytes resemble more the undifferentiated transient amplifying cells of the
growing hair rather than differentiated cells of the hair matrix.
On the other side of differentiation is the transcription factor HES1, suggested to
prevent premature differentiation of melanocytes. Hes1 is reported to be a
mediator of Notch signalling in skin development and in hair follicle maintenance
where it regulates commitment of epidermal keratinocytes to terminal
differentiation [247,253]. Hes1 is expressed in spinous layers and mediates
spinous cell gene induction and thus terminal differentiation of epidermal
keratinocytes [247]. In a mature hair follicle it is most prominent in the inner root
sheath, in matrix cells committed to terminally differentiate to form the hair shaft
[246,247]. On the other hand, in the melanocytic lineage, Notch signalling, acting
through Hes1, plays a crucial role in survival of immature melanoblasts and
melanocyte stem cells, by preventing initiation of apoptosis [194]. Moreover, it
prevents differentiation of melanoblasts and melanocyte stem cells before they
reach the hair bulb and regulates their proper location in the ORS and in the hair
matrix [254]. Therefore it is not surprising that we see a decrease in the number of
PAX3 and HES1‐positive cells in the hair bulb compared to the ORS (10.5% and
23.7%, respectively). What is surprising is that around 28% of PAX3‐positive
epidermal melanocytes are also HES1‐positive, indicating they are not terminally
differentiated.
In summary, it seems that epidermal melanocytes are not all terminally
differentiated and similar to those in the hair follicle they exhibit variable
differentiation status, with a persistent PAX3 expression. Melanocytes in the ORS
of the hair follicle are mostly PAX3 and MITF‐positive and not all are fully
differentiated (23.7% HES1‐positive, 61.5% MLANA‐positive). In the matrix of the
hair bulb the number of PAX3‐positive melanocytes is lower (around 65%), with
only a small proportion still showing a less differentiated phenotype (10.5% HES1‐
positive and 36% MLANA‐positive). Epidermal PAX3‐positive melanocytes show a
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similar profile to those in the ORS (27.9% HES1‐positive, 62% MLANA‐positive).
Interestingly, there are a similar number of MLANA‐positive (but PAX3‐negative)
melanocytes in the epidermis (30.5%) and the hair matrix (40%), in contrast to the
ORS where such cells are rare (3.9%). PAX3 expression seems to correlate with
undifferentiated (co‐expressing HES1 and MITF) and differentiating (co‐
expressing MLANA and MITF) cells, whereas it might be diminished in terminally
differentiated cells (PAX3‐negative but MLANA or MITF‐positive) that are further
along the continuum of differentiation. It is possible that PAX3 is involved in
maintenance of melanocyte “stemness”, at least while they are migrating towards
their destination, either in the hair follicle or the epidermis.
PAX3 in apoptosis
It is also very likely that PAX3 is involved in keeping melanocytes alive, since three
quarters of epidermal and more than half ORS and matrix PAX3‐positive
melanocytes show expression of the PAX3 target, antiapoptotic BCL2L1. PAX3 is
previously reported as an antiapoptotic regulator in tumours, including melanoma
[28,155,156,160‐162].

Several known antiapoptotic factors, such as tumour

suppressors p53, PTEN and BCL2L1, are involved in Pax3‐induced cell survival
[28,225,226]. BCL2L1 is directly transcriptionally regulated by PAX3, and in
rhabdomyosarcoma treatment with PAX3 or BCL2L1 antisense oligonucleotides,
individually or in combination, decreases cell viability to a similar extent,
suggesting that they lie in the same antiapoptotic pathway [226]. Similarly,
BCL2L1 is associated with melanoma cell survival, since its expression correlates
with

melanoma

progression

[255,256]

and

treatment

with

antisense

oligonucleotides resulted in reduction of cell viability [257,258]. However, its
expression is observed in naevi and normal skin [255,256] and in melanocytes it
also affects cell viability [258].
As expected we have observed positive BCL2L2 staining in all normal skin, naevi
and primary melanoma samples analysed. The majority of PAX3‐positive cells in
melanomas and naevi samples and melanocytes in normal skin co‐express BCL2L2,
at a similar frequency. These results support the potential role of PAX3 as one of
many cell survival regulators. The results also indicate that normal melanocytes
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might utilise the same cell survival regulatory pathway as melanoma cells, both in
the epidermis and in hair follicles.
PAX3 in migration
The cell adhesion molecule MCAM has been associated with melanoma
progression and metastatic potential [259‐262]. Even though MCAM is frequently
expressed in naevi [250] its increased expression in melanomas shows significant
correlation with poor disease free survival and mortality [250,259‐261,263,264].
Upregulation of MCAM, together with loss of keratinocyte‐dependence, is one of
the crucial events that allows melanoma cells to invade the dermis and progress to
vertical growth phase (for review see [265]). MCAM can mediate both homotypic
adhesion between melanoma cells, promoting local tumour growth, and
heterotypic adhesion between melanoma cells and endothelial cells of blood
vessels, facilitating metastatic spread [237,262,266].
Pax3‐transfected melanocyte cells show upregulation of MCAM, both at an mRNA
and protein level, suggesting that MCAM is a downstream target of Pax3 [121,204].
Our results confirm co‐expression of PAX3 and MCAM in melanomas and naevi,
mainly in the cells that form nests located in the dermal component of the lesion,
with melanoma samples showing larger number of PAX3, MCAM‐positive cells
compared to naevi. This indicates that some PAX3‐positive cells in naevi and
melanomas have the capability to undergo vertical spread/migration. It suggests
that regulation of migration might be one of the roles of PAX3 in melanoma, as it is
in development, where Pax3 regulates cMet [202].
The frequent observation of MCAM expression in cells of the hair follicle might be
associated with downwards growth into the dermis and migration of follicular
cells. The observation that some PAX3‐positive melanocytes in the ORS show
MCAM expression, in contrast to those in the epidermis, suggests that MCAM is
associated with migration of normal melanocytes from the bulge area to the
developing hair follicle and to the epidermis. Upon reaching the epidermis, MCAM
expression is downregulated. Alternatively, epidermal melanocytes do not arise
and migrate from the bulge, but rather arise from interfollicular melanocyte stem
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cells, similar to those believed to maintain interfollicular epidermal homeostasis
[165,267,268]. Even though some epidermal melanocytes resemble the transient
amplifying melanocytic cells of the hair follicle with respect to their differentiation
status, they are not thought to have the same migratory propensity.
In summary, in addition to detection in the majority of naevus and melanoma cells,
we conclusively show PAX3 expression in melanocytes of normal skin. Epidermal
PAX3‐positive melanocytes, like follicular cells, exhibit a variable differentiation
status; the majority show a more mature phenotype, but a proportion (around
20%) show a less differentiated and proliferative phenotype. Moreover, these
melanocytes frequently show expression of a cell survival marker. Our results
suggest that a previously identified role for PAX3, as a regulator of an
undifferentiated plastic state, may operate in melanocytes of normal skin. This
role, possibly required for cellular response to environmental stimuli, may
predispose a proportion of these cells to a successful malignant transformation as
they are antiapoptotic, undifferentiated and proliferative.
In addition, our findings that PAX3 expression is specific for both melanocytic
lineage and melanocytic lesions, could have potential applications in the clinical
setting, as an immunohistochemical assay for the differential diagnosis of
melanoma. The effectiveness of the commercially available anti‐PAX3 antibodies
and optimisation of staining protocols shown in this paper might also be proved
useful in a clinical setting.
Materials and methods
Sample collection
De‐identified archival tissue samples were obtained from several pathology
laboratories in accordance with the Human Research Ethics Committee of Edith
Cowan University (ethics approval code 07‐189 MEDIC). Written consent was
obtained for the use of patient archival tissue samples. Samples were previously
diagnosed by certified pathologists. 4µm thick formalin fixed paraffin embedded
tissue sections were used for immunohistochemistry and immunofluorescence.
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The

following

samples

were

analysed

by

immunohistochemistry

and

immunofluorescence: 10 normal skins (including 3 hairy, 2 limb and 2 breast skin
samples, and 3 samples had no anatomic location specified), 14 naevi (including 5
intradermal, 6 compound and 3 junctional samples), 15 primary (including 8
superficial spreading melanoma samples, 2 of radial growth phase, and 1 sample
each of acral lentiginous, nodular, neurotropic, recurrent and lentigo maligna
melanoma) and 5 systemic melanoma metastases (2 small bowel and 3 lymph
node). Tissue samples characterized here as normal skins were free of any
melanocytic lesion, having been used for other diagnostic purposes (solar
keratosis, seborrhoeic keratosis and granulomatous folliculitis) or tissue obtained
after breast reduction. Normal skin samples originated mainly from limbs or face
(referred to as sun‐exposed skin) or breast (referred to as reduced sun‐exposed
skin). Additionally, a separate set of 12 archival samples, including 2 normal skin, 5
naevi and 5 primary melanomas as well as 5 cryopreserved lymph node melanoma
metastases were analysed by qRT‐PCR.
RNA extraction and qRTPCT
Total RNA was extracted from the paraffin embedded and cryopreserved tissue
samples using Aurum Total RNA Mini Kit (Bio‐Rad) according to the
manufacturer’s recommendations. Slight modifications were made to the protocol
used for paraffin embedded samples. Mainly, sections were dewaxed in Xylene and
absolute Ethanol (each twice for 10 minutes), before tissue was scratched from the
slides and lysed in a mixture of Tissue Lysis Buffer (High Pure RNA Paraffin Kit,
Roche), Proteinase K and 10% SDS by incubation at 550C overnight.
The quality and integrity of extracted RNA was assessed by gel electrophoresis and
subsequent amplification of the housekeeping gene GAPDH. 250ng of the total
RNA was reverse transcribed with Omniscript RT kit (Qiagen), according to the
manufacturers’ instructions and PCR was performed using Taq DNA Polymerase
(Qiagen). Primers used were, for GAPDH: 5’‐GGG TGT GAA CCA TGA GAA GT‐3’
(forward) and 5’‐GAC TGT GGT CAT GAG TCC T‐3’ (reverse) [269]; and for PAX3:
5’‐AGA CTG ATT ACG CGC TCT CC‐3’ (forward) and 5’‐GGC TGC GAA GAC CAG AAA
C‐3’ (reverse). Real time PCR was performed using iQ SYBR Green Supermix (Bio‐
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Rad). Each sample was run in duplicate and assays included negative controls
(reagents without RNA or cDNA) and positive controls (plasmid DNA containing a
PAX3 insert). The calibration curve was generated using the threshold cycle (Ct) of
8 serial dilutions of plasmid DNA template with known copy number. The Ct value
of the sample was interpolated from the standard curve and mRNA copy number,
mean value and standard deviation were calculated using iQ5 RealTime Detection
System Software (Bio‐Rad Laboratories). The increase in the mean values of mRNA
copy number for each sample relative to that in the normal skin was expressed as a
fold‐change increase in mRNA.
Antibodies
The following primary antibodies were used: mouse monoclonal to PAX3 (DSHB,
1/10), rabbit polyclonal to PAX3 (Invitrogen, 1/500), mouse monoclonal to MITF
(Merck, 1/20), mouse monoclonal to MLANA (Merck, 1/50), rabbit polyclonal to
HES1 (Abcam, 1/100), rabbit monoclonal to BCL2L1 (Abcam, 1/50), rabbit
monoclonal to MCAM (Abcam, 1/500) and rabbit polyclonal to Ki67 (Abcam,
1/25). For immunofluorescent staining the following secondary and tertiary
antibodies were used: anti‐mouse conjugated AlexaFluor‐488 (1/500), anti‐rabbit
conjugated AlexaFluor‐488 (1/500), anti‐mouse conjugated AlexaFluor‐546
(1/500), or biotinylated anti‐rabbit IgG (1/500) linked to streptavidin‐conjugated
AlexaFluor‐546 (1/500). All antibodies were diluted in PBST (0.2% TritonX‐100 in
PBS) together with 1%NGS for immunofluorescent staining.
Immunohistochemistry
Paraffin embedded sections were dewaxed in xylene (3x 5 minutes) and
dehydrated in ethanol series (3x 5 minutes in 100% ethanol, 1 minute in each of
95% and 70% ethanol, and 3x 10 dips in ddH20). Antigen retrieval was routinely
performed in EDTA/Tris, pH 8.0, by heating for 3x 5 minutes in a microwave oven,
at approximately 750 Watts. Slides were left to cool to room temperature for at
least 20 minutes. Sections were washed in PBS and endogenous peroxidases were
blocked with 3% H202 for 10 minutes. After rinsing in PBS, sections were blocked
with 10% FCS for one hour, followed by incubation with primary antibodies for
one hour at room temperature. After washing in PBS, the secondary antibody
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linked to biotin (Dako, LSAB kit) was applied and sections were incubated for 20
minutes at room temperature. After washing in PBS‐Tween20 (0.05%), sections
were incubated with streptavidin conjugated horseradish peroxidase (Dako, LSAB
kit) for 20 minutes at room temperature, washed in PBS‐Tween20, then incubated
with DAB (Dako) for several minutes. The reaction was stopped by washing in
ddH20, and the signal was enhanced by applying a solution of CuSO4 and NaCl, for 3
minutes. Hematoxylin staining was performed before the slides were mounted
with DPX neutral mounting medium. Results were analysed on an Olympus BX51
microscope and images were captured using an Olympus DP71 camera. Controls
with primary antibodies withheld were immunonegative. The specific staining of
nuclear markers PAX3 and MITF was generally distinguishable from the
cytoplasmic melanin deposit in the tissue by their sub‐cellular localisation.
Intensity of PAX3 staining was compared across all samples analysed and
described as either weak or strong.
Immunofluorescence
The same dewaxing, rehydration and antigen retrieval procedures described above
were followed for immunofluorescence. Sections were blocked with 10%NGS for
one hour at room temperature, followed by incubation with primary antibodies at
40C overnight (for rabbit PAX3 and MITF co‐staining) or at room temperature for
one hour (for all other antibodies). After washing in PBS, sections were incubated
with the appropriate secondary antibody (followed by tertiary only for rabbit
PAX3 and HES1) for one hour and washed in PBS. For counterstaining Hoechst
33342 was used. Sections were mounted with FluorSave Reagent (Calbiochem)
and analysed on an epifluorescent Olympus BX51 microscope equipped with an
Olympus DP71 camera. Controls with primary antibodies withheld were
immunonegative. For each sample, quantification of cells positive for a given
marker was performed by analysis of 5‐10 representative regions of the section.
The number of double‐labelled cells was calculated relative to the number of cells
positive for a comparative marker and expressed as a percentage.
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Abstract
The PAX3 transcription factor is the key regulator of melanocyte development
during embryogenesis and is also frequently found in melanoma cells. While PAX3
is known to regulate melanocyte differentiation, survival, proliferation and
migration during development, it is not clear if its function is maintained in adult
melanocytes and melanoma cells. To clarify this we have assessed which genes are
targeted by PAX3 in these cells. We show here that similar to its roles in
development, PAX3 regulates complex differentiation networks in both melanoma
cells and melanocytes, in order to maintain cells as “stem” cell‐like (via NES and
SOX9). We show also that mediators of migration (MCAM and CSPG4) are common
to both cell types but more so in melanoma cells. By contrast, PAX3‐mediated
regulation of melanoma cell proliferation (through TPD52) and survival (via
BCL2L1 and PTEN) differs from that in melanocytes. These results suggest that by
controlling cell proliferation, survival and migration as well as maintaining a less
differentiated “stem” cell like phenotype, PAX3 may contribute to melanoma
development and progression.
Keywords:
PAX3, melanoma, melanocyte

78

Chapter IV – Medic, Rizos and Ziman, 2011
Introduction
Melanoma is an aggressive skin cancer and mortality rates remain high for
advanced stage patients where the five year survival rate is less that 20% [8].
Current therapies have limited success, and while targeted therapies are proving
more successful [30‐32], knowledge of the mechanisms that drive disease
progression is urgently required. Of particular interest here are the key regulators
of cellular process in both normal skin melanocytes and melanoma cells, as
differences between these two are likely to provide strategic clues to the process of
melanoma‐genesis.
The transcription factor, Paired box 3 (PAX3), is at the top of the hierarchy of
genes that regulate melanocyte specification, maintenance of the undifferentiated
state, proliferation and migration during embryonic development (reviewed in
[1]). PAX3 is also highly expressed in melanoma [24,25], where it is shown to
contribute to melanoma cell survival [27,28]; however, it is not known whether it
continues to control pathways of differentiation, migration and proliferation and
whether this contributes to melanoma progression.
In contrast to its well known role in embryonic development and in maintenance
of the undifferentiated postnatal melanocyte stem cell [19], not much is known
about the role of PAX3 in adult epidermal melanocytes, since its expression there
has only recently been confirmed [2,18]. Our own studies indicate that PAX3‐
positive epidermal melanocytes exhibit a variable phenotype, from a more mature
to a less differentiated and proliferative form, frequently showing expression of
the antiapoptotic factor BCL2 like protein 1 (BCL2L1) [2]. Taken together with
other studies [20,163], the results suggest that even in normal adult skin
melanocytes PAX3 regulates differentiation and proliferation, as it does during
development. It seems likely then, that PAX3 would continue to control
maintenance of the undifferentiated state, proliferation and migration, throughout
melanocyte development and maturation, and melanoma‐genesis, possibly playing
a significant role in driving melanoma development and progression.
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To clarify its role and identify any potential differences in the functional repertoire
of PAX3 between melanocytes and melanoma, we analysed its direct target genes,
and assessed their differential activation in each cell type. We show here that PAX3
is similarly involved in promoting a “stem” cell phenotype in both melanoma cells
and melanocytes (via Nestin (NES) and SRY (sex determining region Y)‐box 9
(SOX9)). There is however, a hitherto unreported difference in PAX3 regulation of
melanoma cell proliferation relative to melanocytes (through Tumour protein D52
(TPD52)). We also confirm that its role in cell survival (via BCL2L1 and
Phosphatase and tensin homologue deleted from chromosome 10 (PTEN)) is
distinct for melanoma cells. Moreover, while PAX3 commonly regulates cell
migration through Melanoma cell adhesion molecule (MCAM) and Chondroitin
sulphate proteoglycan 4 (CSPG4) in both melanocytes and melanoma cells, binding
and expression of these genes are significantly enhanced in melanoma cells,
presumably affecting the functional outcome. Therefore, PAX3 may indeed ‘tick all
the boxes’ as an intrinsic factor in melanoma development and progression.
Materials and Methods
Cell culture
Human primary neonatal foreskin melanocytes HEM1455 (Cell Applications) were
cultured as previously described [270]. A2058 metastatic melanoma cells (ATCC)
were cultured in DMEM medium (Invitrogen) supplemented with 10% FBS
(Interpath). Cell cultures were incubated at 37°C in a humidified incubator
supplemented with 5% CO2.
Immunocytochemistry
Immunofluorescent analysis was done as previously described [2]. Briefly, 5x104
cells/ cover slip were grown for 24 hours, as described above. Following fixation in
4% paraformaldehyde, and blocking with 10% NGS, cells were double‐stained with
anti‐PAX3 (Invitrogen, 1/500) and anti‐MITF (Merck, 1/200) antibody overnight.
Controls with primary antibodies withheld were immunonegative.
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Western blotting
Total cellular proteins were extracted using RIPA lysis buffer containing protease
inhibitors (Roche). Proteins (30–50 mg) were resolved on 12% SDS‐
polyacrylamide gels and transferred to Immobilon‐P membranes (Millipore).
Western blots were probed with antibodies against PAX3 (DSHB) and β‐actin
(Abcam), and proteins detected with ECL Western Blot Detection Kit (Amersham).
ChIP
Chromatin immunoprecipitation was performed using the EZ‐Magna ChIP A kit
(Millipore) according to the manufacturer’s recommendations. Briefly, melanocyte
and melanoma cells were fixed in 1% formaldehyde, harvested, lysed, and DNA
was sheared using a Branson450 Sonifier. Immunoprecipitation (IP) was
performed with 5µg of either anti‐PAX3 (from either DSHB or Invitrogen) or anti‐
IgG antibody (Millipore) as negative control. A 2% aliquot of sheared DNA prior to
immunoprecipitation was used as input. All IPs were done in duplicate. Positive
control promoters of Microphthalmia associated transcription factor (MITF) (‐
332/+5) and Dopachrome tautomerase (DCT) (‐186/‐3), encompassing the
confirmed

PAX3

binding

sites

[64,65,187],

were

amplified

with

5’‐

TCCTCCAAAGGGGCATTCTGCT and 5’‐TCCCGAGACACCACCGGAAA (MITF); and 5’‐
TGCCCTCCTGAAATAAAGCC and 5’‐AAGCCAAACACCGTGCTG (DCT). Negative
control primers (Millipore) amplified a non‐related GAPDH promoter sequence. All
PCRs were amplified using a Taq DNA Polymerase kit (Qiagen) for 40 cycles.
qPCR analysis of the gene promoter
Profiling of ChIP samples was done with custom designed ChampionChIP PCR
array (Qiagen) containing 12 genomic sites of interest (Supplementary Table S1).
qPCR analysis was performed according to the manufacturer’s recommendations.
Briefly, PAX3 or IgG immunoprecipitated DNA samples (IPs) and input DNA
samples were loaded with RT2qPCR SYBR Green/Fluorescein Master Mix (Qiagen)
into arrays and amplified for 40 cycles on iQ5 cycler (BioRad). Additionally, MITF,
DCT and GAPDH genomic sites were amplified with KAPA SYBR FAST qPCR Master
Mix (KapaBiosystems) for 40 cycles. Each PCR reaction was performed in duplicate
and mean Ct values were used for quantification. Each IP Ct value was normalised
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against the Input Ct value for the same PCR assay (ΔCt), before the fold enrichment
in PAX3‐IP over negative control IgG‐IP (ΔΔCt) was calculated for each genomic
site. Enrichment for the non‐specific site (GAPDH) was determined to be the
background and only enrichment above this value was considered true enrichment
for each specific genomic site. Specific genomic enrichment was then calculated for
each individual ChIP experiment, by subtracting the background from it, and the
mean value for duplicate ChIP experiments was calculated.
RNA extraction and RTqPCR
Total RNA was extracted from cultured HEM1455 and A2058 cells using either
Isolate RNA Mini Kit (Bioline), or Tryzol reagent (Invitrogen) with a column clean
up (Qiagen). Quantity and quality of RNA were measured with a nanodrop
spectrophotometer and assessed by agarose gel electrophoresis. 250ng of total
RNA was reverse transcribed using Omniscript RT kit (Qiagen) and PCR products
were amplified with either KAPA SYBR FAST qPCR Master Mix (KapaBiosystems)
or SYBR GreenER qPCR SuperMix (Invitrogen), for 40 cycles. Each PCR reaction
was performed in triplicate and the mean Ct value was used to calculate fold
change over GAPDH (ΔΔCt). Primers used for RT‐qPCR are listed in the
supplementary information (Supplementary Table S2).
Statistical analyses
Statistical analyses of specific site enrichment and gene expression were
performed using a Student’s t‐test.
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Results
PAX3 expression in HEM1455 primary melanocytes and A2058 melanoma
cells
We have previously reported persistent PAX3 expression in melanocytic lesions
and normal skin melanocytes, both follicular and epidermal [2]. Here we confirm
PAX3 expression in both HEM1455 and A2058 cell lines (Fig. 4.1), showing slightly
lower (however not statistically significant) PAX3 levels in A2058 compared to
HEM1455 cells. This is most likely due to the variable expression of PAX3 in A2058
cells, as evidenced by differences in PAX3‐staining intensity across the cultured
cells, including some PAX3‐negative cells. Others have also reported high variation
in PAX3 levels across a variety of melanoma cell lines, but more uniform staining
and higher expression in melanocytes [27].

Figure 4.1. PAX3 expression in melanocytes and melanoma cells. (A) PAX3 expression
in A2058 cells confirmed by immunocytochemistry, showing co‐expression of PAX3 with
MITF, a known marker of the melanocytic lineage. (B) PAX3 expression in HEM1455 and
A2058 cells confirmed by western blotting. (C) Graph shows PAX3 mRNA levels in
HEM1455 and A2058 (relative to GAPDH) assessed by RT‐qPCR.
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PAX3 target genes in HEM1455 and A2058 cell lines
In order to assess PAX3 function/s and identify differential regulation mediators
between melanocytes and melanoma cells, we have analysed 12 out of 56 potential
direct PAX3 target genes (Supplementary Table S3). These genes were selected as
indicators of key PAX3‐regulated processes, ie differentiation (SOX9, NES, and
Hairy and enhancer of split 1 (HES1)), proliferation (TPD52, Cyclin A2 (CCNA2),
and Nuclear factor kappa β 2 (NFKβ2)), cell survival (BCL2L1, PTEN, and
Transforming growth factor‐beta 1 (TGFβ1) and migration (MCAM, CSPG4, and CXC
chemokine receptor 4 (CXCR4)).
In addition MITF and DCT, known PAX3 targets in the melanocytic cell lineage,
were chosen as positive controls to assess ChIP assay efficiency. ChIP with anti‐
PAX3 antibody (DSHB) showed enrichment for both MITF and DCT promoters over
the IgG control in A2058 cells, and this was confirmed using a different anti‐PAX3
antibody (Invitrogen), albeit with less efficiency (Fig. 4.2A).
After validating the PAX3 ChIP assay on A2058 cells, we assessed binding of our
selected genes (Table S1) in HEM1455 and A2058 cells. Enrichment in PAX3‐IP
relative to control IgG‐IP was observed for most of the genomic sites analysed (Fig.
4.2B), which is consistent with these genes being direct downstream targets of
PAX3 in these cell types. However, there was no enrichment in NFKβ2 genomic site
in either HEM1455 or A2058, indicating it is not a target of PAX3 in either cell.
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Figure 4.2. PAX3 binding to target genes in melanocytes and melanoma cells. (A)
PAX3 binding to MITF and DCT promoters in A2058 cells was assessed by end‐point PCR.
ChIP assay was performed with two different PAX3 antibodies (from DSHB, lane 3; or
Invitrogen, lane 5) and matching control IgG antibodies (lanes 4 and 7). Non‐specific
GAPDH promoter was included as a negative control for PAX3‐IP; and IP with AcH3
(acetylated Histone H3, lane 6) serves as positive IP control. Blank (lane 1) is no‐template
control for PCR reaction. (B) Graph shows PAX3 binding to potential target genes in
HEM1455 and A2058 cells, quantified by qPCR. For each target site, enrichment in PAX3‐
IP was normalised to the input DNA and calculated as a fold increase over normalised IgG‐
IP. Only enrichment above the enrichment value for the non‐specific site (GAPDH) was
considered true enrichment. Therefore, for each IP, specific promoter enrichment was
subtracted from non‐specific promoter enrichment (which was 5.58‐fold for both
HEM1455 IP1 and 2 and 2.6 and 5.135‐fold for A2058 IP1 and 2, respectively). Asterisk (*)
indicates statistically significant fold difference, p<0.05.

Interestingly the overall fold enrichment at all sites is higher in A2058 compared
to HEM1455, indicating a stronger binding of PAX3 to its targets in melanoma cells.
In melanocytes four genomic sites, NES, TPD52, BCL2L1 and PTEN, do not show
enrichment in PAX3‐IP, suggesting that PAX3 regulates different pathways in
melanocytes and melanoma cells. The fact that these genes are involved in
differentiation (NES), proliferation (TPD52), and cell survival (BCL2L1 and PTEN)
signifies PAX3 involvement in regulation of these processes in melanoma by
instigating melanoma‐exclusive mechanisms.
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In addition, genomic sites for SOX9, MCAM and CSPG4, even though common for
both cell types, show significantly higher fold enrichment in melanoma cells
compared to melanocytes. This suggests that PAX3 utilises the same mechanisms
(via MCAM and CSPG4) to regulate migration of melanocytes and melanoma cells.
In summary, the fourteen potential PAX3 target genes analysed here can be
categorised as follows: i) PAX3 targets specific for melanoma (NES, TPD52, PTEN
and BCL2L1); ii) PAX3 targets common to both melanocytes and melanoma (MITF,
DCT, HES1, SOX9, CCNA2, TGFβ1, MCAM, CSPG4, and CXCR4); and iii) not a PAX3
target, such is NFKβ2).
Expression of PAX3 targets in HEM1455 and A2058
We next analysed the expression of the thirteen identified target genes in the two
cell lines to confirm that the mRNA profile corresponds to PAX3 binding (Fig. 4.3).
Results here show downregulation of MITF, BCL2L1, and PTEN in A2058 compared
to HEM1455, by 4.96*, 2.47, and 1.81*‐fold, respectively (asterisk indicates
statistical significance, p<0.05). HES1 shows no change in expression levels
between the two cell lines (0.86‐fold). By contrast, the remaining nine genes show
upregulation in A2058 cells compared to HEM1455: DCT (2.74), SOX9 (6.13*), NES
(10.66*), CCNA2 (2.17*), TPD52 (6.09*), TGFβ1 (3.24*), MCAM (38.04*), CSPG4
(2.37*), and CXCR4 (11.35*) (asterisk indicates statistical significance, p<0.05).

Figure 4.3. PAX3 “target” gene expression levels in melanocyte and melanoma cells.
Relative expression of PAX3 targets was analysed by RT‐qPCR. Asterisk (*) indicates
statistically significant fold difference, p<0.05
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We observe here a correlation between PAX3 binding to the target gene and its
expression level; ie genes showing statistically significant enrichment in PAX3
binding in the melanoma cells vs. melanocytes, also show a significant difference in
expression levels. Melanoma specific PAX3 targets, NES and TPD52 show
significant upregulation in A2058, whereas BCL2L1 is downregulated although this
is not statistically significant. Also, PTEN is significantly downregulated in
melanoma. Furthermore, targets that are common in melanoma and melanocytes,
but show significantly higher PAX3 binding in melanoma (such as SOX9, MCAM and
CSPG4) also show significant upregulation in A2058 suggesting a role for PAX3 in
their increased activation.
Discussion
To elucidate the role of PAX3 in melanoma relative to its role in melanocytes, we
focused on processes known to be regulated by PAX3 during melanocyte
development that might also be critical for melanoma progression. Fourteen
chosen genes associated with these processes were analysed here as potential
PAX3 targets, and proved to be informative in clarifying PAX3 involvement not just
in melanoma, but also in melanocyte cellular processes.
Traditional

developmental

roles

of

PAX3

in

regulating

differentiation,

proliferation, cell survival and migration, are retained in melanocytes and
melanoma cells, utilising common pathways/ mediators (such are MITF, DCT,
HES1, SOX9, CCNA2, TGFβ1, MCAM, CSPG4, and CXCR4). However, additional
regulatory mechanisms are employed specifically in melanoma (exemplified by
NES, TPD52, PTEN, and BCL2L1). Moreover, several of the common targets, namely
SOX9, MCAM and CSPG4, show significant fold enrichment in melanoma cells
compared to melanocytes, suggesting that PAX3 mediated mechanisms are
amplified in melanoma. Interestingly, those targets that are more strongly
activated in melanoma are those that determine a less differentiated (SOX9 and
NES), more motile (MCAM and CSPG4) cell phenotype, characteristic of melanomas
with a higher metastatic potential [125]. In addition PAX3 targets that appear
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restricted to melanoma cells, promote cell survival (via PTEN) and proliferation
(via TPD52).
For the first time, we identify TPD52 as a novel PAX3 target, and this PAX3‐
mediated activation is restricted to melanoma cells rather than melanocytes.
Overexpression of TPD52 associated with cellular proliferation is frequently
observed in cancer, and in melanoma it is the fifth most upregulated gene
[229,271,272]. Thus we show here that PAX3 regulates melanocyte and melanoma
proliferation [20,163], and it does so in melanoma via TPD52.
We also identify that the clearest difference in PAX3 function between melanoma
and melanocytes is in regulating cell survival. PAX3 binds to antiapoptotic factor
BCL2L1 and tumour suppressor gene PTEN in melanoma cells. PTEN
overexpression results in cell cycle arrest and apoptosis, and mutations and
inactivation of this gene are common in tumours [197,225]. Moreover PAX3 was
previously reported to repress PTEN transcription in rhabdomyosarcoma and
myoblasts [197]. Indeed, we show here strong PAX3 binding and downregulation
of PTEN in melanoma. The strong decrease in expression may be exacerbated by
the presence of three heterozygous PTEN mutations in A2058 cells including a
35bp deletion and two missense point‐mutations [273].
The mechanism of melanocytes and melanoma cell migration appears to be
similar, since it binds to MCAM, CSPG4 and CXCR4 in both cell types, suggesting that
the mere presence of PAX3 predisposes both cells to a highly motile phenotype.
However, this is the first time that MCAM and CSPG4, known to promote cell
motility [274,275], are shown to be direct targets of PAX3. We also confirm PAX3
binding to CXCR4, associated with metastatic spread of melanoma [276]. CXCR4,
and its ligand CXCL12, regulate chemotactic migration and “homing” of tumour
cells to a secondary organ/site, and facilitate tumour cell extravasation [277,278].
While PAX3 might regulate melanocyte and melanoma cell migration via the same
mechanisms, it does so with increased strength in melanoma. By contrast, the low
MCAM expression and PAX3 binding in melanocytes are consistent with low levels
of PAX3/MCAM co‐expression restricted to melanocytes of the growing hair
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follicles of normal skin, whereas epidermal melanocytes show no MCAM
expression [2]. These observations highlight the likelihood of PAX3 involvement in
melanoma progression to metastasis.
The overall higher fold enrichment at all gene sites, observed in melanoma
compared to melanocytes, suggests a higher affinity of PAX3 for its targets in
melanoma, since there is a similar level of PAX3 expression in both cell types. The
increased binding might be due to the upregulation of “appropriate” cofactors in
melanoma cells, providing a more favourable environment for PAX3 binding to
target genes; or perhaps chromatin changes allow increased binding to targets.
PAX3 binding efficiency to genes can also be altered in the presence of competitors
(such as MITF) and transcriptional activation affected by cofactors (like SOX10,
GRG4, DAXX) or antagonists (TGFβ2) [19,64,123]. For example, we did see here a
very high increase of TGFβ2 expression in melanoma cells (180.84‐fold, data not
shown).
Finally, our results show that PAX3 is a key element in the complex regulating
networks defining differentiation in melanocytes and melanoma cells, balancing
the cells between a less or more differentiated state, through MITF, DCT and TRP1
[19,64,76], together with transcription factors SOX9 and HES1, as well as the TGFβ
signalling pathway. We confirm here that MITF, DCT, SOX9 and HES1 are all direct
targets of PAX3. It is evident from our results that regulation of the differentiation
status of melanocytes and melanoma cells operates via PAX3‐regulated
mechanisms. We see exceptionally strong PAX3 binding to SOX9 and HES1 in
melanoma, presumably to maintain the less differentiated phenotype. SOX9
promotes melanocyte differentiation, whereas HES1 maintains a less differentiated
phenotype [254,279]. PAX3 represses SOX9, and activates HES1, whereas TGFβ2
has the opposite effect [123]. However, we do not see the expected changes in
SOX9 and HES1 expression levels in these cells. One likely explanation is the
significant upregulation of TGFβ2 in melanoma, known to antagonise PAX3, which
could override PAX3‐regulated SOX9 repression and HES1 activation.
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Moreover, we find that NES is regulated by PAX3 exclusively in melanoma cells.
NES is thought to mark a subpopulation of quiescent melanoma ‘stem’ cells with
higher metastatic potential [144], which contribute to melanoma progression.
It is interesting to note that even though PAX3 is known to activate MITF, and MITF
expression in melanocytes is very high, its promoter shows minimal occupancy by
PAX3. This suggests limited involvement of PAX3 in transcriptional regulation of
MITF in melanocytes. Indeed, melanocyte transfection with Pax3 did not result in
an increase in Mitf [121], confirming that Pax3 is not required to activate Mitf in
these cells. It is possible that, in contrast to embryonic development, once the
required level of MITF has been established in postnatal melanocytes, PAX3 is no
longer necessary for its maintenance. In melanomas, however, PAX3 might once
again regulate MITF, maintaining low to intermediate levels required to promote
proliferation rather than differentiation [193].
In conclusion, the key transcription factor PAX3 is expressed both in normal
melanocytes and melanoma cells and regulates a number of processes similarly in
both cells. In melanoma cells however, PAX3 appears to have a higher affinity
/binding capacity for target genes, which regulate cell proliferation and cell
survival. Since PAX3 acts as an internal rheostat to regulate cell differentiation, and
maintenance of the stem cell phenotype, its expression in melanocytes and then in
melanoma cells may increase the aggressive phenotype associated with metastatic
melanoma, by promoting proliferation and preventing apoptosis, a lethal mixture.
Moreover, by conferring migratory properties to melanocytes PAX3 predisposes
them to a more motile phenotype upon malignant transformation thus
contributing to metastatic spread of melanoma cells. Future studies to evaluate
PAX3 as a potential target for melanoma treatment are suggested.
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Supplementary data
Table S1. Selected PAX3 target genes included in the custom promoter binding
qPCR array.
ChIPqPCR Assay
cat #

Binding site
position

Biding
sequence

GPH1009779(+)04A

193857155

TTGGTCATGCCCCA

GPH1005991(‐)01A

70117017

CTCGTCACCCAGCC

NES (Nestin)

GPH1015041(+)01A

156646502

CGCGCCACGCCTCG

CCNA2 (Cyclin A2)

GPH1023871(+)02A

1227743650

ATCTTCACGCTCTA

TPD52 (Tumour protein D52)
NFKβ2 (Nuclear factor kappa β 2
(p100))

GPH1026252(+)01A

81083671

CTCGCCGCGGTCCA

GPH1001851(‐)01A

104154208

GCGAGGCGTGACGC

GPH1022053(‐)01A

30311475

CGGAAGCGGGACGG

GPH1001746(‐)02A

89622131

CTCGCCCCGCCCAC

GPH1020707(‐)05A

41863841

ATGGGGTGGGACCA

GPH1016778(+)05A

119183639

ACAGTCTGGGACGA

GPH1018524(‐)05A

76009320

AGTGGCTGTGACCA

GPH1021572(+)01A

136872816

TTGGAGTGTGACAG

GPH1021572(+)01A

136873229

GGGAAGCGTGATGA

Gene
HES1 (Hairy and enhancer of split
1)
SOX9 (SRY (sex determining region
Y)‐box 9)

BCL2L1 (BCL2 like protein 1)
PTEN (Phosphatase and tensin
homologue
deleted
from
chromosome 10)
TGFβ1
(Transforming
growth
factor‐beta isoform 1)
MCAM (Melanoma cell adhesion
molecule)
CSPG4
(Chondroitin
sulphate
proteoglycan 4)
CXCR4 (CXC chemokine receptor 4)

Table S2. Primers used in RT‐qPCR analysis.
Gene

Forward primers

Reverse primer

GAPDH

5’‐TTCTTTTGCGTCGCCAGCCGAG‐3’

5’‐GTGACCAGGCGCCCAATACGA‐3’

PAX3

5’‐AGCCGCATCCTGAGAAGTAA‐3’

5’‐CTTCATCTGATTGGGGTGCT‐3’

MITF

5’‐CGTCTCTCACTGGATTGGTG‐3’

5’‐CCGTTGGGCTTGCTGTATGT‐3’

DCT

5’‐CGACTCTGATTAGTCGGAACTCA‐3’

5’‐GGTGGTTGTAGTCATCCAAGC‐3’

TGFβ2

5’‐CTGTAGCCCCATAACTTGG‐3’

5’‐GAAAGCACGTGGCTCTTGT‐3’

HES1

5’‐AGAAAGATAGCTCGCGGCATTCCA‐3’

5’‐TTCCCCAGCACACTTGGGTCT‐3’

SOX9

5’‐AGCAAGACGCTGGGCAAGCTCTGG‐3’

5’‐CCCGTTCTTCACCGACTTCCTCCG‐3’

NES

5’‐GCGCACCTCAAGATGTCCCTCA‐3’

5’‐GGTGTTTGCAGCCGGGAGTTC‐3’

CCNA2

5’‐AGAGGCCGAAGACGAGACGG‐3’

5’‐TGAATGGTGAACGCAGGCTGTT‐3’

TPD52

5’‐ACATGGACCGCGGCGAGCAA‐3’

5’‐GTGGCACTGATCGTGGCAGCAAC‐3’

NFKβ2

5’‐GCCCAGAGACATGGAGAGTTGCT‐3’

5’‐TGGCTCCTTGGGTTCCACAATGG‐3’

BCL2L1

5’‐CAGGTATTGGTGAGTCGGATCGC‐3’

5’‐GGCTCTCGGCTGCTGCATTGTT‐3’

PTEN

5’‐GCTGGAAAGGGACGAACTGGTGTA‐3’

5’‐CACATAGCGCCTCTGACTGGGAA‐3’

TGFβ1

5’‐GTCACCGGAGTTGTGCGGCA‐3’

5’‐GCAGTGGGCGCTAAGGCGAA‐3’

MCAM

5’‐GGGTACCCCATTCCTCAAGT‐3’

5’‐CTGGGACGACTGAATGTGG‐3’

CSPG4

5’‐GCCTTCACTGTCACTGTCCTGCCT‐3’

5’‐TCCTCAGACCCAGAGTCGCCGT‐3’

CXCR4

5’‐GCCTTCACTGTCACTGTCCTGCCT‐3’

5’‐AGTCCCCTGAGCCCATTTCCTCG‐3’
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Selection of potential PAX3 target genes
Various genes have been reported to be directly regulated by PAX3 in different cell
lineages and at different time points of development. Our interest here, however,
was to identify those that are differentially regulated in melanocytes and
melanoma cells. We initially searched the literature for those genes that show
direct transcriptional regulation by PAX3, as well as those that show
up/downregulation following PAX3 transfection [121,204,280]. Table below lists
56 genes commonly reported to be affected by PAX3 in either melanocytic cells or
tumours. We chose those genes that are indicative of key functional pathways of
proliferation, differentiation, cell survival and migration. Additionally, we
considered those genes that show promoter occupancy by PAX3 as assessed by
ChIP‐sequencing [281] and/or are significant to melanoma development [229]
(Table S1). Our final list included 12 genes potentially regulated by PAX3 in
melanocytes and/or melanoma cells (Table S1), in addition to the MITF and DCT.
Table S3. Potential PAX3 target genes.
Gene

Gene description and function

Gene
expression

PAX3
binding

Melanoma
top genes

Genes involved in melanocytic differentiation:
MITF

Microphthalmia associated
transcription factor (D)

TYR

Tyrosinase (D)

TRP1
DCT /
TRP2

Tyrosinase related protein 1 (D)

Down [204]

Dopachrome tautomerase (D)

Down [19]

HES1

Hairy and enhancer of split 1 (D)
SRY (sex determining region Y)‐
box 9 (D)
Nestin (D)
Cbp/p300‐interacting
transactivator 1
(D, P)

Up [122]

χ [282]

Down [122]

χ [280]
χ [280]

SOX9
NES
CITED1/
MSG1

Up [64,65]
χ [282]
χ [282]

Up [121,280]

Genes involved in proliferation and cell cycle regulation:
CCNA1

Cyclin A1 (P, Ap)

Up [121]

CCNA2

Cyclin A2 (P)

Up [121]

CCNE1

Cyclin E1 (P)

Up [121,204]

TPD52

Tumour protein D52 (P, anti‐Ap)

Up [121]

c‐KIT

C‐kit receptor (P, D, M)

Up [121]

KITL

KIT ligand (P, Ap, M)

Up [121,280]

APOD

Apolipoprotein D (P, D)

Up [121]

χ [280]

**(59th) [229]

χ [280]

**(5th) [228]

*(45th) [228]

93

Chapter IV – Medic, Rizos and Ziman, 2011
Growth factors involved in proliferation and angiogenesis:
TGFβ1
TGFβ2
TGFα
FGF1
FGF2
FGF8
FGF10
FGF17
FGFR1
IGF1R
VEGFC

Transforming growth factor‐beta
isoform 1 (P, Ap, M)
Transforming growth factor‐beta
isoform 2 (P, Ap, An, EMT)
Transforming growth factor‐alpha
(P)
Fibroblast growth factor 1 (P, Ad)
Fibroblast growth factor 2
(P, Ap, An, M)
Fibroblast growth factor 8 (P, An)
Fibroblast growth factor 10
(P, An, M)
Fibroblast growth factor 17 (P, D,
M)
Fibroblast growth factor receptor
1
(P, D)
Insulin‐like growth factor 1
receptor
(P, M, anti‐Ap)
Vascular endothelial growth factor
C (An, M, P)

Up [121]

χ [280]

Up [204]

Χ [281]
**(62nd)
[228]

Up [57]
Up/down [121]
Up [121]
Χ [281]
χ [280]
Χ [279]
χ [280]
Up [121]

χ [280]

Up/down [121]
Χ [279]
Χ [279]
χ [280]

Genes involved in apoptosis:
NF‐Kβ2
BCL2L1
PTEN
MDM1
TIMP2
TIMP3

Nuclear factor kappa B 2 (p100)
(anti‐Ap)
BCL2 like protein 1 (anti‐Ap)
Phosphatase and tensin
homologue deleted from
chromosome 10 (Ap)
Mdm1 nuclear protein homologue
(mouse) (Ap)
Tissue inhibitor of
metalloproteinase 2 (An, D, P)
Tissue inhibitor of
metalloproteinase 3 (Ap, An)

Up [204]

χ [280]

Up [226]

χ [280]

Down [197]

χ [280]
Χ [279]

Up [121]
Up [121,204]/
down [280]

**(120th)
[228]

χ [280]

Genes involved in migration and adhesion:
CSPG4/
MCSP
MCAM/
MUC18

Chondroitin sulphate
proteoglycan 4 / HMW‐MAA (M,
An)
Melanoma cell adhesion molecule
(M, Ad)

CXCR4

CXC chemokine receptor 4 (M)

EPHA2
EPHA4

Ephrin type‐A receptor 2 (M)
Ephrin type‐A receptor 4 (M)

Down [280]
Up [280]

Χ [279]

EPHB2

Down [280]

Χ [279]

VCAM1

Ephrin type‐B receptor 2 (M)
Vascular cell adhesion molecule
(Ad)

S100A6

Calcium binding protein A6 (M, P)

Up [121]

χ [280]

VCAN

Versican (V2 splice variant) (Ad)

Up [204]

χ [280]
Up [121,204]

χ [280]
Χ [279]
χ [280]

**(21st) [228]

Χ [279]
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CNR1

Cannabinoid receptor type 1 (Ap,
Im, )

Up [280]

χ [280]

EMT (epithelial to mesenchimal transition):
CDH3
CDH5
CDH12

Cadherin 3 type 1/ P‐cadherin
(Ad)
Cadherin 5 type 2/ VE‐cadherin
(Ad)
Cadherin 12 type 2/ N‐cadherin 2
(Ad)

Χ [279]

*(3rd) [228]

Χ [279]
Χ [279]

Cancer specific genes:
PRAME
MAGEC3
MAGEA5
MAGEB6
MAGEB18

Melanoma antigen preferentially
expressed in tumours (P, anti‐Ap)
Melanoma antigen family C, 3
(ND)
Melanoma antigen family A, 5
(ND)
Melanoma antigen family B, 6
(ND)
Melanoma antigen family B, 18
(ND)

Up [204]

**(4th) [228]
Χ [279]
Χ [279]

**(28th)
[228]

Χ [279]
Χ [279]

Other genes:
MGP
DMRT2
ST8SIA1
NAA10
CD55
WNT5B

Matrix gla protein (D, M)
Doublesex and mab‐3 related
transcription factor 2 (D)
ST8 alpha‐N‐acetyl‐neuraminide
alpha‐2,8‐sialyltransferase 1 (P)
N (alfa)‐acetyletransferase 10
(P, anti‐Ap)
Complement decay‐accelerating
factor (anti‐Ap, Im)
Wingless‐type MMTV integration
site family, member 5B (D, M, An)

**(20th)
[228]

Down [204]
Χ [279]
χ [280]
Χ [279]
Up [121]

Χ [279]
Χ [279]

**(98th)
[228]

Χ [279]

Table includes list of potential PAX3 target genes, their function, transcriptional regulation
by PAX3 (up or downregulation), and presence of a PAX3 binding site; as well as literature
references. Function is described as: differentiation (D), proliferation (P), migration (M),
adhesion (Ad), apoptosis (Ap), angiogenesis (An), immune response (Im), and not defined
(ND). Χ [4] indicates direct binding assessed by ChIP [281]; and χ [8] indicates presence of
PAX3 binding site according to SABioscience database [282]. Single (*) or double asterisk
(**), followed by the order number, indicate top downregulated or upregulated gene in
melanoma vs. melanocytes, respectively [229].
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Cutaneous melanoma is a neoplasm that arises from melanocytic cells in the skin.
The transcription factor PAX3 is at the top of the hierarchy of factors that regulate
melanocyte specification and differentiation, proliferation, survival and migration
during embryonic development [10‐15]. PAX3 is also highly expressed in
melanoma [2,21‐26], where it is shown to contribute to melanoma cell survival
[27,28]. It is however not known whether PAX3 continues to control pathways of
differentiation, proliferation and migration in melanoma cells and whether this
contributes to melanoma progression.
Taking into account the possibility that metastatic melanoma progression is driven
by melanoma stem‐like cells, and taken together with the analogy between
developmental processes and tumourigenesis, the pivotal role that PAX3 has
during melanocyte development, has instigated us to further investigate PAX3
involvement in melanoma development and progression.
PAX3 expression in melanocytic lesions and normal skin
We initially started with a comparative analysis of PAX3 expression in normal skin,
relative to its expression in a variety of melanocytic lesions, including benign
pigmented naevi, and primary and metastatic melanomas, to see if changes in
PAX3 expression were associated with melanoma progression [2]. Our results
showed persistent PAX3 expression across all melanocytic lesions. When assessed
by RT‐qPCR, PAX3 expression was similar in naevi and primary melanoma
samples, and significantly upregulated in melanoma metastases. However, these
results reflect the overall increase in the number of PAX3‐expressing melanoma
cells in samples of melanoma metastasis, rather than levels of expression per cell.
Immunohistochemical analysis showed no significant correlation between level of
PAX3 protein per cell and melanoma progression. Both intensity of PAX3 staining
and frequency of PAX3‐expresing cells, relative to a known melanocytic marker
MITF, showed similar results for primary melanomas as for naevi and
melanocytes. By contrast, metastatic samples showed slightly lower PAX3 staining
intensity per cell but the overall number of PAX3‐positive cells increased.
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Interestingly, we also observed consistent PAX3 expression in normal
melanocytes, including epidermal melanocytes presumed to be terminally
differentiated mature cells [2]. This was in contrast to the widely accepted belief
that this developmental regulator is ‘switched off’ in differentiated adult
melanocytes,

and

re‐expressed

or

aberrantly

expressed

in

melanoma

[19,20,24,25]. Several conflicting reports created uncertainty as to whether PAX3
expression is retained in adult melanocytes, with only a handful of reports
detailing PAX3 expression in human primary melanocytes [16,17]. By contrast,
murine primary melanocytes were shown to lack endogenous Pax3 [163]. A
detailed study done by He and colleagues [18] confirmed our findings that PAX3
expression is retained in human epidermal melanocytes.
This essentially posed a new question‐ what is the role of PAX3 in differentiated
adult melanocytes? Moreover, does PAX3 persistent expression in melanocytes
contribute to melanoma‐genesis and progression? The likelihood exists that the
same developmental roles for PAX3 are operational in adult melanocytes and
might continue in melanoma. Logically the next focus of our study was to
investigate PAX3 involvement in several developmental regulatory processes,
namely, differentiation, proliferation, survival and migration, in both melanocytes
and melanoma cells.
PAX3 in normal skin melanocyte
The role of PAX3 in melanocyte differentiation is probably the best described role
for PAX3 thus far, balancing melanocyte differentiation with maintenance of the
undifferentiated state [13,19]. We decided to better characterise PAX3‐expressing
melanocytes in terms if their differentiation status, utilising previously identified
markers of a more or less differentiated state, namely MLANA and HES1,
respectively. MLANA is a type III membrane protein, indispensable for correct
functioning of the structural melanosomal protein PMEL, and for pigmentation
[96]. Like other melanogenic genes (TYR, TYRP1, DCT, and PMEL), MLANA
expression is transcriptionaly regulated by MITF, a direct PAX3 dowstream target
[68‐71]. MLANA therefore marks melanocytes that are further down the
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differentiation path. By contrast, the transcriptional repressor HES1, another
direct target of PAX3 [122,123], is found in undifferentiated melanocyte stem cells
of the hair follicle [194].
During the hair cycle, melanocytes are known to progress through stages of
differentiation and maturation, closely associated with their location in the
growing follicle, namely bulge melanocyte stem cells, their differentiating progeny
along the outer root sheath (ORS) and finally mature matrix melanocytes [254].
Utilising co‐expression analysis of PAX3 with MLANA or HES1, we identified the
differentiation status of follicular and epidermal melanocytes; from less
differentiated PAX3, MITF and HES1 positive cells, to more differentiated PAX3,
MITF and MLANA positive cells, and also identified PAX3‐negative, MITF and
MLANA positive cells, which are presumably fully mature melanocytes. We found
that epidermal melanocytes resemble transit amplifying cells of the outer root
sheath, showing similar numbers of undifferentiated and differentiating PAX3‐
expressing cells, and a small number of PAX3‐negative melanocytes. By contrast,
the hair matrix contains much larger numbers of PAX3‐negative mature
melanocytes [2].
Thus melanocytes express PAX3 along the full differentiation continuum, with its
expression diminishing at the very end, in fully mature melanocytes. These cells at
the terminal end of differentiation might be cells close to the end of their life span,
and perhaps there is no need for PAX3 at this point since the melanogenic cascade
is already operational; or perhaps the loss of PAX3 causes their termination, since
loss of PAX3 allow cells to undergo apoptosis [27,28]. Nevertheless, it is obvious
that normal epidermal melanocytes show variable differentiation levels, from less
differentiated to fully mature cells.
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PAX3regulated melanocyte differentiation network
Networks regulating melanocyte differentiation have been established previously
and include the synergistic activity of PAX3 and SOX10 to induce MITF, which then
activates the whole cascade of melanogenic targets (refer to the Figure 1.1.3. in
literature review). However, another member of the SOX family, SOX9 has also
been implicated in melanocyte regulation. SOX9 is commonly expressed in cells of
melanocytic lineage, including normal melanocytes, naevi and melanomas
[16,279,283,284]. In contrast to SOX10, increased levels of SOX9 are found in
differentiating melanocytes, particularly after UVB exposure, playing a role in
melanogenesis by upregulating MITF, DCT and TYR [16,279]. By contrast, the
transcriptional repressor HES1 promotes stem cell maintenance and prevents
premature differentiation [122,123,254]. PAX3 is found to directly regulate both
HES1 and SOX9 during neural crest development [122,123], to differentially
regulate stem cell maintenance and differentiation [285].
We have looked to see if the same PAX3 ‐ HES1, SOX9 regulation axis is operational
in melanocytes. Indeed ChIP experiments show HES1 and SOX9 promoter
occupancy by PAX3, supporting our hypothesis [3]. Moreover, we observed PAX3
binding to the DCT promoter, an event shown to direct melanocyte stem cell
maintenance [19]. It does seem then that PAX3 is promoting or maintaining a less
differentiated melanocyte phenotype via HES1, SOX9 and DCT, shown for the first
time here to act together in regulating adult epidermal melanocytes. Interestingly,
the well known MITF activation by PAX3, known to drive differentiation seems to
be lost in adult epidermal melanocytes; we did not observe PAX3 binding to the
MITF promoter in melanocytes in any of our experiments. Similarly Pax3
transfection in murine melanocytes did not result in upregulation of Mitf or
upregulation of other melanogenic factors [121].
Therefore, regulation of melanocyte differentiation, more complex than initially
proposed, is driven by a network of factors, including transcription factors PAX3,
SOX10, SOX9, MITF, and HES1, and downstream effectors TYR, TYRP1, DCT,
MLANA, and PMEL. Moreover, several of the components of this network have
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been shown to be affected by two major signalling pathways, Wnt and TGFβ.
Canonical Wnt signalling pathway is shown to be essential both during hair cycle
and associated melanocyte renewal and melanogenesis, mainly affecting MITF
activation thus promoting melanocyte differentiation [19,118,149,150]. On the
other hand, TGFβ signalling is required for maintenance of bulge melanocyte stem
cells [117]. Moreover, it antagonises MITF function reducing melanosome
maturation and pigmentation, but also antagonises Wnt signalling, by upregulating
Wnt inhibitors [20,124,125,286,287].
Furthermore, TGFβ also suppresses PAX3 and has the opposite effect on HES1 and
SOX9 activation to that of PAX3 [20,122,123]. So, perhaps a feedback loop
functions between these two factors to maintain melanocyte plasticity, and confers
on cells the ability to switch between less and more differentiated phenotypes,
given the bidirectional regulation of TGFβ and PAX3 [20,58,121].
Even though PAX3 maintains cells in a less differentiated state, it remains
expressed even in cells that are undergoing differentiation, hence we see its co‐
expression with markers of differentiated melanocytes, like MLANA. It is likely to
regulate other cellular processes at this point, like proliferation, survival or
migration. It is possible therefore that a loss of PAX3 in terminally differentiated
mature melanocytes might signal their terminal end point, and apoptosis.
Significance of PAX3 expression in normal melanocytes
Several studies, undoubtedly show an antiapoptotic role for PAX3 [27,28],
suggesting regulation of BCL2L1, p53 and PTEN as mediators of this action
[28,55,197,226].
Here we looked at BCL2L1 and PTEN as potential targets of PAX3 in melanocytes
and melanoma cells. We observe co‐expression of PAX3 and BCL2L1 in a similar
proportion of cells in normal melanocytes, naevi and primary melanomas. No co‐
expression was observed in metastatic melanoma samples, where in fact only one
sample was positive for BCL2L1 [2]. These results do suggest PAX3‐mediated
survival via BCL2L1. However, ChIP experiments show no PAX3 binding to BCL2L1
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at all in melanocytes, and low binding in a metastatic melanoma cell line [3]. Taken
together, these results could mean that PAX3 acts as a transcriptional repressor of
BCL2L1, and because it does not bind in melanocytes, both PAX3 and BCL2L1 do
co‐express in the same cell, whereas in metastatic melanoma cells PAX3 binds to
BCL2L1, preventing transcription, therefore co‐expression is not observed; lower
levels of BCL2L1 mRNA observed in melanoma cells, by RT‐qPCR, support this
view.
Alternatively, PAX3 does activate BCL2L1 (as others have suggested), and we see
co‐expression in most of our samples, but the promoter region we have chosen for
ChIP experiments might not be correct. Another explanation might lie in
alternative BCL2L1 isoforms shown to have different biological functions; the
longer isoform 1 (also known as Bcl‐xl) is antiapoptotic, whereas the shorter
isoform 2 (also known as Bcl‐s) is proapoptotic [288]. These two transcripts do
however share the same promoter, in which case we cannot be sure which of them
is regulated by PAX3 in our experiments. Both of the transcripts are shown to be
expressed in normal skin and melanoma samples, but in different proportions
[255]. Presumably the most likely explanation is that the antiapoptotic role of
PAX3 in melanocytes is via other factors and not BCL2L1.
An interesting observation is that a proportion of epidermal melanocytes in sun
exposed normal skin are proliferative [2]. A causal relationship has been
established between sun exposure, PAX3 upregulation and increased melanocyte
proliferation [20]. Cyclin A2 (CCNA2) is upregulated in melanocytes following PAX3
transfection [121], and in our ChIP experiments we observed low enrichment of
the CCNA2 promoter in melanocytes, suggesting that PAX3 regulation of
melanocytic proliferation might be via this general cell cycle regulator. However,
PAX3 binding to CCNA2 is much more prominent in the melanoma cell line. PAX3‐
knockdown in melanoma cells has been shown to inhibit cell proliferation; and
induce cell cycle arrest in S and G2/M phases, both of which require CCNA for
progression through S phase and entry to M phase [27]. These results further
support regulation of proliferation, as a generic role for PAX3, in both melanocytes
and melanoma cells.
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Besides its expected involvement in melanocyte differentiation and survival, it is
interesting to observe PAX3 binding to promoters of genes associated with
migration, namely MCAM, CSPG4 and CXCR4, suggesting that regulation of
migration is a common feature of PAX3 in melanocytes, as it is during development
and tumourigenesis. It also suggests that melanocytes have an intrinsic propensity
to migrate. This feature is required for normal hair follicle regeneration [289], and
sub‐bulge region of hair follicle shows overexpression of MCAM in outer root
sheath, where melanocytes reside [192]. Consistent with these results, we have
observed PAX3 and MCAM co‐expressing melanocytes in the growing hair follicle,
but not in epidermal melanocytes [2]. MCAM upregulation in melanoma is
associated with metastatic progression [229], and PAX3‐transfection into
melanocytes or medulloblastoma cells has been previously shown to result in
MCAM upregulation [121,204].
CSPG4 is a chondroitin sulphate proteoglycan that promotes cell motility and
invasion

by

recruiting

specific

MT‐MMPs

(membrane

type

matrix

metalloproteinases) and MMPs to the cell membrane [290,291]. Interestingly,
CSPG4 was found expressed in many cancers including melanoma [292].
Treatments targeting CSPG4 specifically inhibit melanoma growth in vivo and in
vitro [293,294]. CSPG4 has also been associated with epidermal and follicular stem
cells, where it is believed to contribute to their patterning and distribution
[295,296].
CXCR4 is a chemokine receptor associated with the metastatic spread and
progression of many tumours, including melanoma [276,297‐300]. CXCR4, and its
ligand CXCL12, regulate chemotactic migration and “homing” of tumour cells to a
secondary organ/site, and facilitate tumour cell extravasation [278,297,301].
CXCL12 and CXCR4 are shown to similarly regulate melanocyte stem cell migration
and their proper positioning during hair cycle [302]. It was shown that CXCR4 is
upregulated by PAX3‐FKHR in rhabdomyosarcomas [206,280,281,303].
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From these results it is clear that melanocytic cells possess the potential and in fact
the need to migrate. This intrinsic ability of melanocytes to migrate could possibly
contribute to the aggressive and motile phenotype of transformed melanoma cells.
The fact that all of the genes associated with metastatic progression of melanoma
tested here, such as MCAM, CSPG4 and CXCR4, are shown here to be direct targets
of PAX3 in both melanocytes and melanoma cells, strongly supports the role of
PAX3 in regulating cell motility, possibly contributing to melanoma dissemination.
Differential mechanisms of PAX3 regulation in melanoma
In addition to PAX3‐regulated processes that are common in melanocytes and
melanoma cells, such as stem‐like cell maintenance, proliferation and migration,
we have identified here some melanoma exclusive PAX3 targets, such as TPD52
and PTEN, which may differentially mediate melanoma cell proliferation, and
prevent apoptosis.
TPD52 has a role in membrane trafficking and its overexpression has been
reported in numerous cancers [304‐308]; in melanoma it is the fifth most highly
upregulated gene [229].
PTEN mutations and inactivation are often found in tumours, and overexpression
of functional PTEN results in cell cycle arrest and apoptosis [197,225,309]. PAX3
was previously reported to repress PTEN transcription in rhabdomyosarcoma and
myoblasts [197], and here we show that it might do the same in melanoma.
Normally, PTEN regulates progression through the G1 cell cycle check point, by
negatively regulating PI3K/AKT signalling, through the cell cycle inhibitor (CDK
inhibitor) p27Kip1 [197]. PTEN also directly regulates p53 activity [198,199]. Loss
of functional PTEN (due to mutations or transcriptional suppression) results in the
loss of apoptosis and uncontrolled proliferation.
Another differential PAX3 target in melanoma cells is intermediate filament Nestin
(NES), a neuroectodermal stem and progenitor cell marker that is also present in
hair follicle stem cells [310,311]. Its expression has been reported in melanocytes,
naevi and melanomas [312‐315]. In melanomas stronger staining and increased
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numbers of NES positive cells correlate with more advanced stages [312]. NES‐
positive stage I and II melanomas correlate with worse prognosis [315], and
increased numbers of NES‐positive circulating melanoma cells correlate with
tumour burden, number of metastatic sites and to shorter overall survival [316].
NES marks a subpopulation of melanoma cells with stem cell like properties, as
does ABCB5 [144,147]. It is therefore suggested to be an indicator of less
differentiated and more aggressive melanomas [312] and is implicated in cell
migration and metastasis [317]. Stem‐like cell maintenance therefore seems to be
the generic role of PAX3, not just in melanocytic but also in other PAX3‐associated
lineages (such are muscle and neurons).
What is interesting is that PAX3 binding to a common melanocyte and melanoma
target SOX9 is significantly higher in melanoma cells. Besides promoting
pigmentation, SOX9 might also regulate proliferation, since its overexpression
induces a significant decrease in cell proliferation and G1 cell cycle arrest via p21
upregulation (direct binding of SOX9 to p21 promoter) [283]. Additionally,
increased levels of SOX9 in melanoma reduce PRAME (preferentially expressed
antigen in melanoma) proteins and restore sensitivity to retinoic acid treatment
[283]. Therefore, by repressing SOX9 in melanomas, PAX3 might not only drive a
less differentiated phenotype, but might also promote their proliferation and drug
resistance.
PAX3 regulation of melanoma cell proliferation and survival, however, seems to be
driven by mechanisms distinct from those in melanocytes; this is in contrast to cell
differentiation and migration mediators, commonly regulated by PAX3 in both
melanocytes and melanoma cells. These results provide strong support for our
hypothesis that PAX3 contributes to melanoma progression by conferring to cells
less differentiated, proliferative, migratory, and antiapoptotic properties, leading
these cells to a proliferative motile aggressive phenotype in melanoma.
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Proliferative vs. aggressive motile melanoma cell phenotype and how does
PAX3 fit into this
High levels of cellular heterogeneity are observed in many melanomas with
identification of a subpopulation of cells with invasive properties believed to be
responsible for tumour dissemination and metastatic seeding. It is not still clear
how some melanoma cells gain this ability; whether through acquisition of
additional mutations [104,106], and/or having arisen from a defined
subpopulation

of

slow‐cycling

self‐renewing

melanoma

stem‐like

cells

[239,240,318‐320]. The latter assumes that tumours are hierarchically organised,
with a small subpopulation of tumourigenic cells with self‐renewing capacity that
generate phenotypically diverse nontumourigenic progeny, in a similar manner to
normal stem cell differentiation [126]. However, even after intensive effort to fully
characterise melanoma stem‐like cells, research has yielded conflicting results, and
has failed to clearly identify uniform sets of markers for these cells (for review see
[29,126]). Some groups suggest that most melanoma cells (not just rare stem cells)
actually have tumourigenic capacity [148,321‐323].
Another, more recent, concept suggests that most melanoma cells have the ability
to switch between less and more active malignant states [124,287,322]. According
to this model melanoma metastasis and phenotypic heterogeneity are driven by
specific gene expression programs that are imposed by

the cellular

microenvironment, rather than by accumulation of genetic events. Melanoma cells
are able to respond to microenvironmental changes by switching between a highly
proliferative (low metastatic potential, leading to tumour growth), and highly
invasive phenotype (motile and stem cell‐like, resulting in tumour dissemination).
A highly proliferative cell phenotype shows Wnt and MITF‐driven gene expression
profiles with susceptibility to TGFβ‐mediated inhibition of proliferation. By
contrast, a highly invasive cell phenotype shows a TGFβ‐driven gene expression
profile, with downregulation of Wnt signalling, MITF and downstream
differentiation markers, and low pigmentation [124,125,324].
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In support of this concept, an elegant study by Pinner and colleagues [287] has
shown that low or non pigmented melanoma cells contained within the primary
lesion are motile and these cells enter the vasculature; however this same low
pigmented phenotype is not maintained at the secondary site, suggesting
phenotype switching. They have identified these low pigmented motile melanoma
cells as having high BRN2 (PUO class 3 homeobox 2 (POU3F2)) and high TGFβ
expression. The phenotype switch is bidirectional, but the preference is from Brn2
high to low, or from low pigmented (less differentiated) motile to more
differentiated, pigment‐producing cells.
Transcriptional regulator BRN2 (also known as POU3F2, or N‐Oct‐3 and N‐Oct‐5
when it forms a complex with DNA) is also involved in melanocyte differentiation
and melanogenesis; high expression is observed in unpigmented melanoma and
melanoblast cultures, whereas pigmented melanocytes and melanoma cell lines
show low BRN2 expression [16,188,325,326]. BRN2 plays a role in maintaining an
undifferentiated melanocytic phenotype through TYR and MITF repression
[16,188,325,327], and reduced levels of BRN2 upon differentiation are
accompanied

by

melanosome

maturation

and

increased

pigmentation

[16,326,328]. Additionally, Brn2 is associated with melanoma cell proliferation,
and its regulation has been linked to two major pathways associated with
melanoma tumourigenesis. Activation of Brn2, as a result of either oncogenic
BRAF activity [329], or Wnt/β‐catenin signaling [330], enhances melanoma cell
proliferation. Similarly, BRN2 ablation in melanoma results in decreased
proliferation and tumourigenicity [327,331].
Melanoma cells therefore exhibit phenotypic plasticity and toggle between more or
less differentiated cells, through a bidirectional reversible process of phenotype
switching in response to the environment. This fits into our concept of a role for
PAX proteins in adult tissues that is to regulate cell plasticity, driving their
response to environmental cues [52]. Factors characterising both proliferative
more differentiated (Wnt signalling, and MITF) and less differentiated motile
(BRN2, and TGFβ signalling) phenotype are strongly associated with PAX3. In fact
BRN2 has been shown to form protein‐protein interaction with key melanocytic
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transcription factors PAX3 and SOX10 [332], but also to directly bind to the Pax3
promoter to stimulate its expression [221,222]. Even though functional
interactions between PAX3 and BRN2 on one side, and TGFβ on the other, further
support a link between PAX3 and the ability of melanoma cells to switch
phenotype in response to environmental changes, further studies are required to
clarify the precise nature of the interaction between these factors.
PAX3 could therefore be an intrinsic factor in melanocyte and melanoma cell
plasticity, controlling their ‘appropriate’ response. As our results suggest it can
promote a less differentiated stem‐like cell phenotype (via HES1, SOX9, NES, DCT),
but might also switch cells to an MITF‐driven pigmented, differentiated phenotype;
in corroboration we do see PAX3 binding to the MITF promoter in melanoma cells,
but not in melanocytes.
In melanoma cells PAX3 bound more frequently to genes involved in determining a
less differentiated, motile phenotype, compared to those involved in proliferation
and survival [3]. This might reflect the characteristics of the metastatic melanoma
cell line used here, A2058, shown to have low pigmentation, with high BRN2 levels
[16,188,326]. Nevertheless, significantly higher enrichment of TPD52, and PTEN,
relative to melanocytes, signifies additional differential regulatory mechanisms are
operating in melanoma to regulate their proliferation and survival.
By controlling the crucial cellular processes (such as proliferation, cell survival and
migration), as well as promoting a less differentiated stem‐like cell phenotypes,
PAX3 indeed ‘ticks all the boxes’ as an intrinsic factor driving melanoma
development and progression. Moreover, PAX3 seems capable of translating
environmental signals into cellular response.
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Limitations of the study
This study has conclusively shown continuous expression of the melanocytic
developmental regulator, PAX3, in adult normal epidermal melanocytes [2], and
this was also confirmed later by He and colleagues [18]. A study from the USA
however, reports no PAX3 expression in normal skin and naevi, and expression is
only observed in a small proportion of melanomas [24]. This discrepancy might be
attributed to the methodology, but might also be a reflection of the geographic
origin of the samples used for these studies. It has been shown that UV‐induced
TGFβ reduction results in PAX3 upregulation and melanocyte proliferation, linking
PAX3 expression to the extent of sun exposure [20]. There might therefore be a
difference between melanoma and skin samples originating from the Northern vs
the Southern hemisphere, related to the amount of sun exposure and UV radiation.
The limitation of our study is that a relatively small number of normal skin
samples were tested which originated from different anatomical locations.
Additional normal skin samples, from both exposed and non sun‐exposed areas are
required to address this anomaly.
Another limitation of this study relates to the cell lines used for PAX3 target
analysis. One metastatic melanoma cell line and one neonatal human epidermal
melanocyte primary culture were used for the study. Neonatal melanocytes are
known to exhibit different culturing capacity compared to adult epidermal
melanocytes. On the other hand the A2058 melanoma cell line is a highly
metastatic low pigmented cell line. Further experiments using additional cell lines,
in particular adult epidermal melanocytes and a less aggressive melanoma cell line,
might provide additional information.
Results from this study provide, for the first time, several novel findings, such as a
continuous expression of PAX3 across the whole range of melanocytic cells, from
melanoblasts, throughout adult melanocytes, through to melanocytic lesions. We
have also identified novel PAX3 targets and mechanisms differentially regulated in
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melanoma cells, compared to melanocytes. These results add to our knowledge of
melanocyte biology, opening a new perspective on PAX3 and its role in melanoma
progression.
Future directions
This study has identified differential and common PAX3 targets in melanocytes
and melanoma cells, implicating it in regulation of proliferation, survival and
migration, as well as in maintenance of a less differentiated cell state, in both cell
types. Further investigation is however required to clarify the precise mechanisms
of PAX3 regulation of these processes. We have observed that PAX3 binding to its
targets, and presumably its activity, is more prominent in melanoma cells
compared to melanocytes; however the exact reasons for this are not known.
Neither is it known why some PAX3 targets are different in melanoma cells to
those in melanocytes.
The main query arising from this study is how does PAX3 employ different
mechanisms of action in different cell types? What are the factors that
modulate/enhance PAX3 activity in melanoma, and how does that translate into
the functional outcome? Further investigation including functional and
mechanistic analysis of PAX3 regulation of downstream pathways in melanoma is
required to answer these questions.
One possible explanation lies in different PAX3 isoforms. By alternative splicing, a
single PAX3 gene is able to encode multiple isoforms, that differ in the structure of
their paired, homeodomain and/or transactivation domains, and ultimately in
binding activity and function [177‐179]. For example, the inclusion of Glutamine
(Q) within the linker region between the paired HTH motifs (PAX3Q+ isoform),
alters the binding affinity of the paired domain compared to the Q‐ isoform
[333,334]. In addition to the Q+ and Q‐ isoforms at least eight more PAX3 isoforms
have been reported to date (named as PAX3A‐I) [11,151,168,177]. Two shorter
isoforms, PAX3A and B, both lack the homeodomain and the C‐terminus; while the
other longer isoforms differ in the structure of the transactivation domain.
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Different PAX3 transcripts are shown to differentially impact on cellular processes,
when transfected into a nontumourigenic murine melanocyte cell line. PAX3C, D
and H transcripts for example increase cell transformation, proliferation, migration
and survival; whereas PAX3A and B exhibit the opposite effect, and PAX3E and G
reduce melanocyte growth and increase apoptosis [163]. Interestingly, PAX3C and
PAX3D transcripts are more commonly expressed in melanomas [168], suggesting
these isoforms might be driving melanoma progression. It is possible that
differences observed between PAX3‐regulated pathways in melanoma and
melanocytes could be attributed to different predominant isoforms in each cell
type. Therefore, the expression pattern of PAX3 transcripts in melanoma cells lines
vs. melanocytes needs to be thoroughly investigated.
Another possible determinant of differential PAX3 activity in melanoma is
posttranslational modification of the PAX3 protein. Several recent studies have
reported that PAX3 protein modifications, such is ubiquitination or acetylation, can
switch PAX3 activity from promoting myogenic and neuronal stem cell
maintenance to initiating a differentiation program [218,285]. Similarly, changing
patterns of Pax3 phosphorylation (at Ser205, 201, and 209) have been seen in
proliferating compared to differentiating mouse primary myoblasts [216,335,336].
According to the model proposed by Dietz and colleagues [336], the initial
phosphorylation of Ser205 by CK2 in proliferating myoblasts promotes the GSKβ‐
dependant

phosphorylation

of

Ser201,

followed

by

the

subsequent

dephosphorylation of Ser205. Upon induction of differentiation, phosphorylation
at Ser205 is completely abolished, whereas phosphorylation at Ser201 persists,
and is accompanied by a rapid increase in phosphorylation at Ser209. Loss of
phosphorylation at Ser209, consistent with a decrease in Pax3 expression, is
observed after 4 hours of differentiation. The authors further suggest that the
presence of a single phosphorylation at Ser201 after 8 hours of differentiation is
sufficient to target Pax3 for degradation; which is an essential step for the
progression of the differentiation program in activated satellite cells [218].
Transient Pax3 expression is observed in proliferative intermediate progenitor cell
populations during satellite cell activation [337], but its sustained expression was
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found to inhibit myogenic differentiation and maintain myogenic progenitors in an
undifferentiated state [218]. Pax3 protein stability is regulated by the
ubiquitin/proteasome system. Monobiquitination (at the two C‐terminal lysine
residues, K475 and K437) by Taf1, targets Pax3 for proteasomal degradation, via
Rad23B‐shuttling to the proteasome [218,338].
Interestingly the same two lysine residues, K475 and K437, have been recently
shown to be critical for acetylation as well, associated with Pax3‐regulated
neuronal differentiation [285]. Acetylated Pax3 may downregulate Hes1 and
upregulate Neurog2, resulting in switching from stem cell proliferation to neuronal
differentiation. Acetylated Pax3 is a substrate for NAD‐dependant deacetylase
sirtuin 1 (SIRT1), associated with stem cell maintenance; and in the presence of
SIRT1 Pax3 is deacetylated and thus able to activate Hes1 and repress Neurog2
transcription, maintaining undifferentiated cell state [285].
Pax3 deacetylation is also found to correlate with melanogenesis and possibly with
melanocytic differentiation [339]. Histone deacetylase HDAC10 is found to
physically interact with Pax3 via its paired domain, forming a ternary complex that
maintains Pax3 in a deacetylated state; however, it is not clear if it actively
deacetylates Pax3. HDAC10 decreases repressional activity of Pax3 and co‐
repressor KAP1 on Pax3‐target promoters, namely MITF, TRP1 and DCT, thus
activating melanogenic program in a murine melanoma cell line B16F10 [339].
It is possible that similar mechanisms are involved in determining differential
roles for PAX3 in melanocytes vs melanoma. However, the above mentioned
modifications still have to be assessed in melanocytes and melanoma cells.
Finally, PAX3 regulation of cell proliferation, migration and apoptosis in
melanocytes and melanoma cells and the mechanism of PAX3 regulation of its
downstream targets need to be confirmed in vitro. Several studies have reported
effects of either exogenous PAX3 expression or PAX3 silencing on melanocyte and
melanoma cell behaviour [27,28,163], but the effect of PAX3 silencing or
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overexpression on the expression of PAX3 target genes identified in this study also
need to be confirmed. Finally, these processes need to be confirmed in vivo.
Overall, our findings support an importance of PAX3 for melanocytic lineage and
give insight into its role in adult melanocytes. Moreover, they open a new
perspective on melanoma progression and role of PAX3 in melanoma‐genesis.
Here we have paved the way for future studies on the differential role of PAX3 in
melanocytes and melanoma, and provided the basis for several prospective
projects.
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